Publications

Age and sex are associated with Alzheimer’s disease neuropathology in Down syndrome. Andrews EJ, Ngo PT, Pascual JR, Gonzalez F, Phelan M, Wright ST, Harp J, Schmitt F, Lai F, Lao PJ, Brickman AM, Kofler J, Ikonomovic MD, Head E; Alzheimer’s Biomarker Consortium-Down Syndrome. Alzheimers Dement. 2025 Jul 17; 21:e70408. PMID: 40673442, DOI: 10.1002/alz.70408.

Leptin levels are associated with body mass index and Alzheimer’s disease in Down syndrome. Sordo L, Du A, Sandadi V, Dustagheer FB, Pascual J, Ngo P, Hom CL, Doran E, Head E. Alzheimers Dement. 2025 Jul 9; 21(7):e70448. PMID: 40635163, DOI: 10.1002/alz.70448.

Common neuropathologic change drivers of hippocampal sclerosis of ageing. Woodworth DC, Lou JJ, Yong WH, Head E, Corrada MM, Nelson PT, Sajjadi SA. Brain. 2025 Jul 7; 148(7):2400-2411. PMID: 40323260, DOI: 10.1093/brain/awaf158.

Joint spatial associations of amyloid beta and tau pathology in Down syndrome and preclinical Alzheimer’s disease: cross-sectional associations with early cognitive impairments. Fu JF, Garimella A, Lapointe A, Aye WWT, Chen CD, Lee JH, Krinsky-McHale SJ, Zaman S, Lott IT, Hom C, Ances B, Head E, Mapstone M, Lai F, Handen BL, Laymon CM, Hartley SL, Christian BT, Rentz DM, Johnson KA, Rosas HD, Price JC; Alzheimer Biomarkers Consortium–Down Syndrome. Alzheimers Dement. 2025 Jul; 21(7):e70424. Epub 2025 Jun 30. PMID: 40588723, DOI: 10.1002/alz.70424.

Gait variability as a marker of white matter integrity in individuals with Down syndrome. Leach EM, Powell DK, Glueck AC, Head E, Ibrahim MW, Anderson-Mooney AJ, Van Pelt KL, Harp JP, Schmitt FA, Bahrani AA. Alzheimers Dement. 2025 Jul; 21(7):e70407. Epub 2025 Jun 27. PMID: 40579790, DOI: 10.1002/alz.70407.

Prediction of amyloid and tau brain deposition and cognitive decline in people with Down syndrome using plasma biomarkers: a longitudinal cohort study. Janelidze S, Collij LE, Mattsson-Carlgren N, Antill A, Laymon CM, Lott I, Rosas HD, Minhas DS, Luo W, Zaman S; Alzheimer’s Biomarker Consortium–Down Syndrome investigators; Mapstone M, Head E, Lai F, Hartley SL, Ances BM, Krinsky-McHale SJ, Lee JH, Ossenkoppele R, Christian BT, Handen BL, Hansson O. Lancet Neurol. 2025 Jul; 24(7):591-600. Epub 2025 Jun 18. PMID: 40541209, DOI: 10.1016/S1474-4422(25)00158-9.

Modified cued recall test: longitudinal analysis of test versions and item recall in adults with Down syndrome. Schworer EK, Handen BL, Krinsky-McHale S, Hom CL, Clare ICH, Harp JP, Pulsifer MB, Mapstone M, Head E, Christian BT, Hartley SL; Alzheimer Biomarker Consortium‐Down Syndrome. J Intellect Disabil Res. 2025 Jul; 69(7):569-581. Epub 2025 Apr 20. PMID: 40254895, DOI: 10.1111/jir.13237.

Physical activity as a resistance or resilience mechanism in Down syndrome Alzheimer’s disease. Fleming VL, Peven J, Helsel BC, Ptomey LT, Clina J, Barry A, Ances BM, Handen BL, Christian BT, Laymon C, Zammit M, Head E, Mapstone M, Okonkwo O, Hartley SL; Alzheimer Biomarkers Consortium–Down Syndrome. Alzheimers Dement (NY). 2025 Jun 27; 11(3):e70127. PMID: 40584896, DOI: 10.1002/trc2.70127.

PET-measured amyloid beta accumulates at an accelerated rate in Down syndrome compared to neurotypical populations. McVea A, DiFilippo A, McLachlan M, Betcher B, Zammit M, Betthauser TJ, Converse A, Murali D, Stone C, Hartley S, Johnson S, Tudorascu DL, Laymon CM, Cohen AD, Minhas D, Luo W, Mathis C, Lao PJ, Ances B, Zaman S, Mapstone M, Head E, Handen BL, Christian BT; Alzheimer Biomarkers Consortium–Down Syndrome. Alzheimers Dement. 2025 Jun 24; 21(6):e70357. PMID: 40556306, DOI: 10.1002/alz.70357.

Longitudinal study of body mass index in relation to Alzheimer’s disease pathology and symptomatology in Down syndrome. Fleming VL, Helsel BC, Ptomey LT, Handen BL, Krinsky-McHale SJ, Hom CL, Zammit M, Minhas D, Luo W, Laymon C, Lee JH, Lott I, Cohen A, Ances BM, Brickman AM, Pulsifer M, Clare ICH, Rosa HD, Lai F, Harp J, Schmitt F, Price J, Zaman SH, Head E, Mapstone M, Christian BT, Okonkwo O, Hartley SL; Alzheimer’s Biomarkers Consortium–Down Syndrome. Alzheimers Dement. 2025 Jun 22; 21(6):e70387. PMID: 40545561, DOI: 10.1002/alz.70387.

The future of biomarkers for vascular contributions to cognitive impairment and dementia (VCID): proceedings of the 2025 annual workshop of the Albert Research Institute for white matter and cognition. Lennon MJ, Karvelas N, Ganesh A, Whitehead S, Sorond FA, Durán Laforet V, Head E, Arfanakis K, Kolachalama VB, Liu X, Lu H, Ramirez J, Walker K, Weekman E, Wellington CL, Winston C, Barone FC, Corriveau RA. Geroscience. 2025 Jun 21. Epub ahead of print. PMID: 40542975, DOI: 10.1007/s11357-025-01746-y.

Down syndrome with Alzheimer’s disease brains have increased iron and associated lipid peroxidation consistent with ferroptosis. Thorwald MA, Godoy-Lugo JA, Kerstiens E, Garcia G, Kim M, Shemtov SJ, Silva J, Durra S, O’Day PA, Mack WJ, Hiniker A, Vermulst M, Benayoun BA, Higuchi-Sanabria R, Forman HJ, Head E, Finch CE. Alzheimers Dement. 2025 Jun 19; 21(6):e70322. PMID: 40536124, DOI: 10.1002/alz.70322.

The history of Down syndrome-associated Alzheimer’s disease; past, present, and future. Maure-Blesa L, Carmona-Iragui M, Lott I, Head E, Wisniewski T, Rafii MS, Espinosa J, Flórez J, Mobley WC, Holland A, Strydom A, Zaman S, Fortea J. Alzheimers Dement. 2025 Jun 5; 21(6):e70158. PMID: 40469048, DOI: 10.1002/alz.70158.

Applying machine learning to assist in the morphometric assessment of brain arteriolosclerosis through automation. Lou JJ, Chang P, Nava KD, Chantaduly C, Wang HP, Yong WH, Patel V, Chaudhari AJ, Vasquez R, Monuki E, Head E, Vinters HV, Magaki S, Harvey DJ, Chuah CN, DeCarli CS, Williams CK, Keiser M, Dugger BN. Free Neuropathol. 2025 Jun 2; 6:12. PMID: 40510864, DOI: 10.17879/freeneuropathology-2025-6387.

Sex differences in mitochondrial free-carnitine levels in subjects at-risk and with Alzheimer’s disease in two independent study cohorts. Bigio B, Lima-Filho RAS, Barnhill O, Sudo FK, Drummond C, Assunção N, Vanderborght B, Beasley J, Young S, Korman A, Jones DR, Sultzer DL, Ferreira ST, Mattos P, Head E, Tovar-Moll F, De Felice FG, Lourenco MV, Nasca C. Mol Psychiatry. 2025 Jun; 30(6):2573-2583. Epub 2025 Jan 7. PMID: 39774493, DOI: 10.1038/s41380-024-02862-5.

SARS-CoV-2 infection of human cortical cells is influenced by the interaction between aneuploidy and biological sex: insights from a Down syndrome in vitro model. Lioudyno MI, Sevrioukov EA, Olivarria GM, Hitchcock L, Javonillo DI, Campos SM, Rivera I, Wright ST, Head E, Fortea J, Wisniewski T, Cuello AC, Do Carmo S, Lane TE, Busciglio J. Acta Neuropathol. 2025 May 30; 149(1):54. PMID: 40445428, DOI: 10.1007/s00401-025-02895-2.

Apolipoprotein E abundance is elevated in the brains of individuals with Down syndrome-Alzheimer’s disease. Farrell C, Buhidma Y, Mumford P, Heywood WE, Hällqvist J, Flores-Aguilar L, Andrews EJ, Rahimzadah N, Taso OS, Doran E, Swarup V, Head E, Lashley T, Mills K, Toomey CE, Wiseman FK. Acta Neuropathol. 2025 May 19; 149(1):49. PMID: 40387921, DOI: 10.1007/s00401-025-02889-0.

The Alzheimer’s Biomarker Consortium-Down Syndrome (ABC-DS): a 10-year report. Handen BL, Mapstone M, Hartley S, Andrews H, Christian B, Lee JH, Tudorascu D, Hom C, Ances BM, Zaman S, Krinsky-McHale S, Brickman AM, Rosas HD, Cohen A, Petersen M, O’Bryant S, Harp JP, Schmitt F, Ptomey L, Burns J, Lott IT, Lai F, Silverman W, Laymon C, Head E; Alzheimer’s Biomarker Consortium–Down Syndrome. Alzheimers Dement. 2025 May 15; 21(5):e70294. PMID: 40371686, DOI: 10.1002/alz.70294.

Correlating hippocampal and amygdala volumes with neuropathological burden in Down syndrome and Alzheimer’s disease and related neurodegenerative pathologies using 7T postmortem MRI. Liou JJ, Li J, Berardinelli J, Jin H, Santini T, Noh J, Farhat N, Wu M, Aizenstein HJ, Mettenburg JM, Yong WH, Head E, Ikonomovic MD, Ibrahim TS, Kofler JK; Alzheimer Biomarker Consortium—Down Syndrome. J Neuropathol Exp Neurol. 2025 May 1; 84(5):364-378. PMID: 40063697, DOI: 10.1093/jnen/nlaf010.

Longitudinal investigation of gait and Alzheimer’s disease in adults with Down syndrome. Barry A, Peven JC, Handen BL, Bolt D, Krinsky-McHale SJ, Hom CL, Clare ICH, Glueck A, Harp J, Schmitt F, Zammit M, Minhas D, Luo W, Laymon C, Price J, Lee JH, Lott I, Cohen A, Ances BM, Pulsifer M, Rosa HD, Lai F, Zaman SH, Head E, Mapstone M, Christian BT, Hartley SL; Alzheimer Biomarker Consortium‐Down syndrome. Alzheimers Dement. 2025 Apr 28; 21(4):e70211. PMID: 40289844, DOI: 10.1002/alz.70211.

Resistance and resilience to Alzheimer’s disease in Down syndrome. Boyle R, Koops EA, Ances B, Andrews EJ, Arenaza-Urquijo EM, Bejanin A, Brickman AM, Buckley RF, Clas GS, Costello E, Coughlan GT, Conley AC, Deng F, de Paula Faria D, Edwards N, Flores-Aguilar L, Fortea J, Ghazi Saidi L, Head E, Hom CL, Koenig K, Lao P, Lengyel I, Li YJ, Loi S, Loughrey D, McGlinchey E, Newhouse P, Pertierra L, Prokopiou PC, Qi Q, de Paula França Resende E, Russell J, Scanlon CE, Schneider C, Schultz SA, Seto M, Shaka S, Soldan A, Vaqué Alcázar L, Weng Y, Wilson JE, Zaman SH, Zsadányi SE, Hartley S. Alzheimers Dement. 2025 Apr 28; 21(4):e70151. Erratum in: Alzheimers Dement. 2025 May; 21(5):e70302, DOI: 10.1002/alz.70302. PMID: 40289889, DOI: 10.1002/alz.70151.

Behavioral and psychological symptoms of dementia and Alzheimer’s disease progression in Down syndrome. Jenkins MR, Peven JC, Kubic L, Handen BL, Krinsky-McHale SJ, Hom CL, Lee A, Tudorascu DL, McLachlan M, Zammit M, Minhas D, Luo W, Laymon C, Lee JH, Lott I, Cohen A, Ances BM, Rosas HD, Lai F, Zaman SH, Head E, Mapstone M, Christian BT, Hartley SL; Alzheimer Biomarker Consortium-Down syndrome. J Neurodev Disord. 2025 Apr 11; 17(1):19. PMID: 40217501, DOI: 10.1186/s11689-025-09604-w.

The striatum is an early, accurate indicator of amyloid burden using [¹¹C]PiB in Down syndrome: comparison of two radiotracers. McLachlan M, Bettcher B, McVea A, DiFilippo A, Zammit M, LeMerise L, Rouanet J, Price J, Tudorascu D, Laymon C, Keator D, Lao P, Brickman AM, Fryer T, Hartley S, Ances BM, Rosas HD, Johnson S, Betthauser T, Stone CK, Zaman S, Handen B, Head E, Mapstone M, Christian BT, Investigators AD. Alzheimers Dement. 2025 Apr 6; 21(4):e70141. PMID: 40189783, DOI: 10.1002/alz.70141.

Daily mindfulness practice with and without slow breathing has opposing effects on plasma amyloid beta levels. Nashiro K, Cahn BR, Choi P, Lee HRJ, Satchi S, Min J, Yoo HJ, Cho C, Mercer N, Sordo L, Head E, Choupan J, Mather M. medRxiv [Preprint]. 2025 Mar 11:2025.03.10.25323695. PMID: 40162262, DOI: 10.1101/2025.03.10.25323695.

Calcineurin inhibition may prevent Alzheimer disease in people with Down syndrome. Dohl J, Treadwell Z, Norris C, Head E. Alzheimers Dement. 2025 Mar 5; 21(3):e70034. PMID: 40042516, DOI: 10.1002/alz.70034.

Locus coeruleus MRI contrast, cerebral perfusion, and plasma Alzheimer’s disease biomarkers in older adults. Dutt S, Bachman SL, Dahl MJ, Li Y, Yew B, Jang JY, Ho JK, Nashiro K, Min J, Yoo HJ, Gaubert A, Nguyen A, Blanken AE, Sible IJ, Marshall AJ, Kapoor A, Alitin JPM, Hoang K, Rouanet J, Sordo L, Head E, Shao X, Wang DJJ, Mather M, Nation DA. Neurobiol Aging. 2025 Mar; 147:12-21. Epub 2024 Nov 27. PMID: 39637519, DOI: 10.1016/j.neurobiolaging.2024.11.008.

Amyloid-β predominant Alzheimer’s disease neuropathologic change. Kovacs GG, Katsumata Y, Wu X, Aung KZ, Fardo DW, Forrest SL, Nelson PT; Alzheimer’s Disease Genetics Consortium, Bowen JD, Crane PK, Jarvik GP, Keene CD, Larson EB, McCormick WC, McCurry SM, Mukherjee S, Kowall NW, McKee AC, Stern RA, Baldwin CT, Farrer LA, Jun G, Lunetta KL, Honig LS, Vonsattel JP, Williamson J, Small S, Barral S, Reitz C, Vardarajan BN, Mayeux R, Burke JR, Hulette CM, Welsh-Bohmer KA, Gearing M, Lah JJ, Levey AI, Wingo TS, Apostolova LG, Farlow MR, Ghetti B, Saykin AJ, Spina S, Faber KM, Foroud TM, Albert MS, Lyketsos CG, Troncoso JC, Frosch MP, Green RC, Growdon JH, Hyman BT, Tanzi RE, Potter H, Dickson DW, Ertekin-Taner N, Graff-Radford NR, Parisi JE, Petersen RC, Boeve BF, Allen M, Carrasquillo MM, Younkin SG, Duara R, Buxbaum JD, Goate AM, Sano M, Masurkar AV, Wisniewski T, Bigio EH, Mesulam M, Weintraub S, Vassar R, Kaye JA, Quinn JF, Woltjer RL, Barnes LL, Yu L, Evans DA, Henderson V, Fallon KB, Harrell LE, Marson DC, Roberson ED, DeCarli C, Jin LW, Olichney JM, Kim R, LaFerla FM, Monuki E, Head E, Sultzer D, Geschwind DH, Vinters HV, Chesselet MF, Galasko DR, Brewer JB, Boxer A, Karydas A, Kramer JH, Miller BL, Rosen HJ, Seeley WW, Burns JM, Swerdlow RH, Van Eldik LJ, Albin RL, Lieberman AP, Paulson HL, Arnold SE, Trojanowski JQ, Van Deerlin VM, Cantwell LB, Kuzma AP, Malamon J, Naj AC, Qu L, Schellenberg GD, Valladares O, Wang LS, Zhao Y, Hamilton RL, Kamboh MI, Lopez OL, Becker JT, Cao C, Raj A, Smith AG, Chui HC, Miller CA, Ringman JM, Schneider LS, Bird TD, Sonnen JA, Yu CE, Grabowsk T, Peskind E, Raskind M, Li G, Tsuang DW, Asthana S, Atwood CS, Carlsson CM, Sager MA, Chin NA, Craft S, Cairns NJ, Morris JC, Cruchaga C, Strittmatter S, Reiman EM, Beach TG, Huentelman MJ, Hardy J, Kauwe JSK, Hakonarson H, Blacker D, Montine TJ, Bush WS, Haines JL, Lerner AJ, Zhou X, Beecham GW, Carney RM, Cuccaro ML, Gilbert JR, Hamilton-Nelson KL, Kunkle BW, Martin ER, Pericak-Vance MA, Vance JM, Myers AJ, Leverenz JB, De Jager PL, Katz MJ, Lipton RB, Pavlik V, Massman P, Darby E, Rodriguear M, Khaleeq A, Royall DR, Stevens A, Ory M, DeToledo JC, Wilms H, Johnson K, Perez V, Hernandez M, Wilhelmsen KC, Tilson J, Chasse S, Barber RC, Fairchild TJ, O’Bryant SE, Knebl J, Hall JR, Johnson L, Mains D, Alvarez L, Gamboa A, Paydarfar D, Bertelson J, Woon M, Ayres G, Aguirre A, Palmer R, Polk M, Adams PM, Huebinger RM, Reisch JS, Rosenberg RN, Cullum M, Williams B, Quiceno M, Hynan L, Smith J, Davis B, Nguyen T, Rogaeva E, George-Hyslop PS. Brain. 2025 Feb 3; 148(2):401-407. PMID: 39417691, DOI: 10.1093/brain/awae325.

A neuropathology case report of a woman with Down syndrome who remained cognitively stable: implications for resilience to neuropathology. Liou JJ, Lou J, Flores-Aguilar L, Nakagiri J, Yong W, Hom CL, Doran EW, Totoiu MO, Lott I, Mapstone M, Keator DB, Brickman AM, Wright ST, Nelson B, Lai F, Xicota L, Dang LT, Li J, Santini T, Mettenburg JM, Ikonomovic MD, Kofler J, Ibrahim T, Head E; Alzheimer Biomarker Consortium‐Down Syndrome. Alzheimers Dement. 2025 Feb; 21(2):e14479. Epub 2025 Jan 27. PMID: 39868632, DOI: 10.1002/alz.14479.

Decoding brain structure to stage Alzheimer’s disease pathology in Down syndrome. Kennedy JT, Wisch JK, Dincer A, Roman J, Gordon BA, Handen B, Benzinger TLS, Head E, Mapstone M, Christian BT, Tudorascu DL, Laymon CL, Hartley SL, Lao P, Brickman AM, Zaman SH, Ances BM; ABC‐DS and DIAN Consortia. Alzheimers Dement. 2025 Feb; 21(2):e14519. Epub 2025 Jan 14. PMID: 39807622, DOI: 10.1002/alz.14519.

Calcineurin/NFAT inhibitors maintain cognition in a preclinical prevention study in an aging canine model of Alzheimer disease. Sordo L, Ubele MF, Boaz KA, Mefford JL, Jones ED, McCarty KL, van Rooyen HY, Smiley J, Bembenek Bailey SA, Perpich JA, Meacham B, Powell DK, Bresch F, Crump JW, Phelan MJ, Noche JA, Stark CE, Puskás LG, Norris CM, Head E. Neurobiol Aging. 2025 Feb; 146:1-14. Epub 2024 Nov 10. PMID: 39547056, DOI: 10.1016/j.neurobiolaging.2024.11.003.

Beat-to-beat blood pressure variability, hippocampal atrophy, and memory impairment in older adults. Lohman T, Sible I, Engstrom AC, Kapoor A, Shenasa F, Head E, Sordo L, Alitin JPM, Gaubert A, Nguyen A, Rodgers KE, Bradford D, Nation DA. Geroscience. 2025 Feb; 47(1):993-1003. Epub 2024 Aug 5. PMID: 39098984, DOI: 10.1007/s11357-024-01303-z.

Iron-associated lipid peroxidation in Alzheimer’s disease is increased in lipid rafts with decreased ferroptosis suppressors, tested by chelation in mice. Thorwald MA, Godoy-Lugo JA, Garcia G, Silva J, Kim M, Christensen A, Mack WJ, Head E, O’Day PA, Benayoun BA, Morgan TE, Pike CJ, Higuchi-Sanabria R, Forman HJ, Finch CE. Alzheimers Dement. 2025 Jan 29; 21(1):e14541. PMID: 39876821, DOI: 10.1002/alz.14541.

Association of medial temporal lobe cerebrovascular reactivity and memory function in older adults with and without cognitive impairment. Kapoor A, Dutt S, Engstrom AC, Alitin JPM, Lohman T, Sible IJ, Marshall A, Shenasa F, Gaubert A, Bradford DR, Sordo L, Shao X, Rodgers K, Head E, Wang DJ, Nation DA. Neurology. 2025 Jan 14; 104(1):e210210. Epub 2025 Jan 9. PMID: 39787444, DOI: 10.1212/WNL.0000000000210210.

Imagine, discover, inspire: proceedings of the 4th international conference of the Trisomy 21 Research Society. Flores-Aguilar L, Hamlett ED, Araya P, Barone E, Bhattacharyya A, Carmona- Iragui M, Chan L, Christian B, Costa ACS, Costanzo F, Del Hoyo Soriano L, Dierssen M, Eichler EE, Fisher E, Galbraith M, Ghosh S, Gimenez S, Guedj F, Guidi S, Iulita MF, Mobley W, Pelleri MC, Potier MC, Rabin KR, Rachubinski A, Rebillat AS, Rubenstein E, Saternos H, Sordo L, Strydom A, Valle-Tamayo N, Waugh KA, Yu E, Zeldich E, Busciglio J, Head E. Neuromolecular Med. 2025 Jan 5; 27(1):5. PMID: 39756004, DOI: 10.1007/s12017-024-08824-y.

Neuropathology of trisomy 21 mosaicism in a case with early-onset dementia. Ngo PT, Pascual JR, Wright S, Williams CK, Magaki S, Yong WH, Vinters HV, Ringman JM, Head E. Alzheimers Dement. 2025 Jan; 21(1):e14394. Epub 2024 Dec 10. PMID: 39655579, DOI: 10.1002/alz.14394.

Spontaneous cerebrovascular reactivity at rest in older adults with and without mild cognitive impairment and memory deficits. Engstrom AC, Alitin JPM, Kapoor A, Dutt S, Lohman T, Sible IJ, Marshall AJ, Shenasa F, Gaubert A, Ferrer F, Nguyen A, Bradford DR, Rodgers K, Sordo L, Head E, Shao X, Wang DJJ, Nation DA. Alzheimers Dement. 2025 Jan; 21(1):e14396. Epub 2024 Nov 18. PMID: 39555916, DOI: 10.1002/alz.14396.

Blood biomarkers in Down syndrome: facilitating Alzheimer’s disease detection and monitoring. Petersen ME, Flores-Aguilar L, Head E, Montoliu-Gaya L, Strydom A, Pape SE, Fortea J, Ashton NJ, Udeh-Momoh C, O’Bryant SE, German D, Despa F, Mapstone M, Zetterberg H. Alzheimers Dement. 2025 Jan; 21(1):e14364. Epub 2024 Nov 13. PMID: 39535517, DOI: 10.1002/alz.14364.

The mediating role of plasma glial fibrillary acidic protein in amyloid and tau pathology in Down’s syndrome. Boerwinkle AH, Wisch JK, Handen BL, Head E, Mapstone M, Rafii MS, O’Bryant SE, Krinsky-McHale SJ, Lai F, Rosas HD, Zaman S, Lott IT, Tudorascu D, Zammit M, Brickman AM, Lee JH, Ances BM; Alzheimer’s Biomarker Consortium‐Down Syndrome. Alzheimers Dement. 2025 Jan; 21(1):e14359. Epub 2024 Nov 13. PMID: 39535359, DOI: 10.1002/alz.14359.

Spatial and single-nucleus transcriptomic analysis of genetic and sporadic forms of Alzheimer’s disease. Miyoshi E, Morabito S, Henningfield CM, Das S, Rahimzadeh N, Shabestari SK, Michael N, Emerson N, Reese F, Shi Z, Cao Z, Srinivasan SS, Scarfone VM, Arreola MA, Lu J, Wright S, Silva J, Leavy K, Lott IT, Doran E, Yong WH, Shahin S, Perez-Rosendahl M, Head E, Green KN, Swarup V; Alzheimer’s Biomarkers Consortium–Down Syndrome. Nat Genet. 2024 Dec; 56(12):2704-2717. Epub 2024 Nov 22. PMID: 39578645, DOI: 10.1038/s41588-024-01961-x.

Timeline to symptomatic Alzheimer’s disease in people with Down syndrome as assessed by amyloid-PET and tau-PET: a longitudinal cohort study. Schworer EK, Zammit MD, Wang J, Handen BL, Betthauser T, Laymon CM, Tudorascu DL, Cohen AD, Zaman SH, Ances BM, Mapstone M, Head E, Christian BT, Hartley SL; Alzheimer’s Biomarker Consortium–Down Syndrome. Lancet Neurol. 2024 Dec; 23(12):1214-1224. Epub 2024 Nov 20. PMID: 39577922, DOI: 10.1016/S1474-4422(24)00426-5.

The effects of mosaicism on biological and clinical markers of Alzheimer’s disease in adults with Down syndrome. Xicota L, Dang LT, Lee A, Krinsky-McHale S, Pang D, Melilli L, O’Bryant S, Henson RL, Laymon C, Lai F, Rosas HD, Ances B, Lott I, Hom C, Christian B, Hartley S, Zaman S, Head E, Mapstone M, Jin Z, Silverman W, Schupf N, Handen B, Lee JH; Alzheimer’s Biomarker Consortium–Down Syndrome. EBioMedicine. 2024 Dec; 110:105433. Epub 2024 Nov 4. PMID: 39500037, DOI: 10.1016/j.ebiom.2024.105433.

Evaluating the updated LATE-NC staging criteria using data from NACC. Woodworth DC, Nguyen KM, Sordo L, Scambray KA, Head E, Kawas CH, Corrada MM, Nelson PT, Sajjadi SA. Alzheimers Dement. 2024 Dec; 20(12):8359-8373. Epub 2024 Oct 1. PMID: 39352226, DOI: 10.1002/alz.14262.

Transcript errors generate amyloid-like proteins in human cells. Chung CS, Kou Y, Shemtov SJ, Verheijen BM, Flores I, Love K, Del Dosso A, Thorwald MA, Liu Y, Hicks D, Sun Y, Toney RG, Carrillo L, Nguyen MM, Biao H, Jin Y, Jauregui AM, Quiroz JD, Head E, Moore DL, Simpson S, Thomas KW, Coba MP, Li Z, Benayoun BA, Rosenthal JJC, Kennedy SR, Quadrato G, Gout JF, Chen L, Vermulst M. Nat Commun. 2024 Oct 7; 15(1):8676. PMID: 39375347, DOI: 10.1038/s41467-024-52886-2.

Lecanemab and vascular-amyloid deposition in brains of people with Down syndrome. Liu L, Saba A, Pascual JR, Miller MB, Hennessey EL, Lott IT, Brickman AM, Wilcock DM, Harp JP, Schmitt FA, Selkoe DJ, Chhatwal JP, Head E. JAMA Neurol. 2024 Oct 1; 81(10):1066-1072. PMID: 39158850, DOI: 10.1001/jamaneurol.2024.2579.

Cerebrovascular disease is associated with Alzheimer’s plasma biomarker concentrations in adults with Down syndrome. Edwards NC, Lao PJ, Alshikho MJ, Ericsson OM, Rizvi B, Petersen ME, O’Bryant S, Aguilar LF, Simoes S, Mapstone M, Tudorascu DL, Janelidze S, Hansson O, Handen BL, Christian BT, Lee JH, Lai F, Rosas HD, Zaman S, Lott IT, Yassa MA, Gutierrez J, Wilcock DM, Head E, Brickman AM; Alzheimer’s Biomarkers Consortium–Down Syndrome. Brain Commun. 2024 Sep 25; 6(5):fcae331. PMID: 39403075, DOI: 10.1093/braincomms/fcae331.

Single-nucleus multi-omics identifies shared and distinct pathways in Pick’s and Alzheimer’s disease. Shi Z, Das S, Morabito S, Miyoshi E, Stocksdale J, Emerson N, Srinivasan SS, Shahin A, Rahimzadeh N, Cao Z, Silva J, Castaneda AA, Head E, Thompson L, Swarup V. bioRxiv [Preprint]. 2024 Sep 8:2024.09.06.611761. PMID: 39282421, DOI: 10.1101/2024.09.06.611761.

Unique pathology in the locus coeruleus of individuals with Down syndrome. Saternos H, Hamlett ED, Guzman S, Head E, Granholm AC, Ledreux A. J Alzheimers Dis. 2024; 101(2):541-561. Epub 2024 Aug 28. PMID: 39213062, DOI: 10.3233/JAD-240043.

Myo-inositol and total NAA in the hippocampus are linked to CSF tau pathology in cognitively normal older adults. Noche JA, Vanderlip C, Wright S, Sordo L, Head E, Stark C. bioRxiv [Preprint]. 2024 Aug 9:2024.08.09.607353. PMID: 39211099, DOI: 10.1101/2024.08.09.607353.

Amyloid age and tau PET timeline to symptomatic Alzheimer’s disease in Down syndrome. Schworer EK, Zammit MD, Wang J, Handen BL, Betthauser T, Laymon CM, Tudorascu DL, Cohen AD, Zaman SH, Ances BM, Mapstone M, Head E, Klunk WE, Christian BT, Hartley SL; Alzheimer Biomarker Consortium–Down Syndrome. medRxiv [Preprint]. 2024 Aug 9:2024.08.08.24311702. PMID: 39211859, DOI: 10.1101/2024.08.08.24311702.

Comprehensive assessment of TDP-43 neuropathology data in the National Alzheimer’s Coordinating Center database. Woodworth DC, Nguyen KM, Sordo L, Scambray KA, Head E, Kawas CH, Corrada MM, Nelson PT, Sajjadi SA. Acta Neuropathol. 2024 Jun 19; 147(1):103. PMID: 38896163, DOI: 10.1007/s00401-024-02728-8.

Central autonomic network dysfunction and plasma Alzheimer’s disease biomarkers in older adults. Lohman T, Kapoor A, Engstrom AC, Shenasa F, Alitin JPM, Gaubert A, Rodgers KE, Bradford D, Mather M, Han SD, Head E, Sordo L, Thayer JF, Nation DA. Alzheimers Res Ther. 2024 Jun 8; 16(1):124. PMID: 38851772, DOI: 10.1186/s13195-024-01486-9.

High-resolution structures of amyloid-β and tau aggregates in individuals with Down syndrome. Fernandez A, Vidal R, Head E. Nat Struct Mol Biol. 2024 Jun; 31(6):859-860. Epub 2024 Mar 29. PMID: 38553643, DOI: 10.1038/s41594-024-01254-1.

Cerebrovascular disease emerges with age and Alzheimer’s disease in adults with Down syndrome. Lao P, Edwards N, Flores-Aguilar L, Alshikho M, Rizvi B, Tudorascu D, Rosas HD, Yassa M, Christian BT, Mapstone M, Handen B, Zimmerman ME, Gutierrez J, Wilcock D, Head E, Brickman AM. Sci Rep. 2024 May 29; 14(1):12334. PMID: 38811657, DOI: 10.1038/s41598-024-61962-y.

Neuropathological findings in Down syndrome, Alzheimer’s disease and control patients with and without SARS-COV-2: preliminary findings. Granholm AE, Englund E, Gilmore A, Head E, Yong WH, Perez SE, Guzman SJ, Hamlett ED, Mufson EJ. Acta Neuropathol. 2024 May 27; 147(1):92. PMID: 38801558, DOI: 10.1007/s00401-024-02743-9.

Age-related brain atrophy and the positive effects of behavioral enrichment in middle-aged beagles. Noche JA, Radhakrishnan H, Ubele MF, Boaz K, Mefford JL, Jones ED, van Rooyen HY, Perpich JA, McCarty K, Meacham B, Smiley J, Bembenek Bailey SA, Puskás LG, Powell DK, Sordo L, Phelan MJ, Norris CM, Head E, Stark CEL. J Neurosci. 2024 May 15; 44(20):e2366232024. PMID: 38561226, DOI: 10.1523/JNEUROSCI.2366-23.2024.

A pathway linking pulse pressure to dementia in adults with Down syndrome. Rizvi B, Lao PJ, Sathishkumar M, Taylor L, Queder N, McMillan L, Edwards NC, Keator DB, Doran E, Hom C, Nguyen D, Rosas HD, Lai F, Schupf N, Gutierrez J, Silverman W, Lott IT, Mapstone M, Wilcock DM, Head E, Yassa MA, Brickman AM. Brain Commun. 2024 May 9; 6(3):fcae157. eCollection 2024. PMID: 38764776, DOI: 10.1093/braincomms/fcae157.

The interactive effect of intra-beat and inter-beat blood pressure variability on neurodegeneration in older adults. Lohman T, Shenasa F, Sible I, Kapoor A, Engstrom AC, Dutt S, Head E, Sordo L, M Alitin JP, Gaubert A, Nguyen A, Nation DA. medRxiv [Preprint]. 2024 May 3:2024.05.01.24306724. PMID: 38746307, DOI: 10.1101/2024.05.01.24306724.

Comparison of tau spread in people with Down syndrome versus autosomal-dominant Alzheimer’s disease: a cross-sectional study. Wisch JK, McKay NS, Boerwinkle AH, Kennedy J, Flores S, Handen BL, Christian BT, Head E, Mapstone M, Rafii MS, O’Bryant SE, Price JC, Laymon CM, Krinsky-McHale SJ, Lai F, Rosas HD, Hartley SL, Zaman S, Lott IT, Tudorascu D, Zammit M, Brickman AM, Lee JH, Bird TD, Cohen A, Chrem P, Daniels A, Chhatwal JP, Cruchaga C, Ibanez L, Jucker M, Karch CM, Day GS, Lee JH, Levin J, Llibre-Guerra J, Li Y, Lopera F, Roh JH, Ringman JM, Supnet-Bell C, van Dyck CH, Xiong C, Wang G, Morris JC, McDade E, Bateman RJ, Benzinger TLS, Gordon BA, Ances BM; Alzheimer’s Biomarker Consortium-Down syndrome; Dominantly Inherited Alzheimer Network. Lancet Neurol. 2024 May; 23(5):500-510. Epub 2024 Apr 15. PMID: 38631766, DOI: 10.1016/S1474-4422(24)00084-X.

Cognitive and functional performance and plasma biomarkers of early Alzheimer’s disease in Down syndrome. Schworer EK, Handen BL, Petersen M, O’Bryant S, Peven JC, Tudorascu DL, Lee L, Krinsky-McHale SJ, Hom CL, Clare ICH, Christian BT, Schupf N, Lee JH, Head E, Mapstone M, Lott I, Ances BM, Zaman S, Brickman AM, Lai F, Rosas HD, Hartley SL; Alzheimer Biomarker Consortium‐Down Syndrome. Alzheimers Dement (Amst). 2024 Apr 14; 16(2):e12582. eCollection 2024 Apr-Jun. PMID: 38623384, DOI: 10.1002/dad2.12582.

Whole genome-wide sequence analysis of long-lived families (Long-Life Family Study) identifies MTUS2 gene associated with late-onset Alzheimer’s disease. Xicota L, Cosentino S, Vardarajan B, Mayeux R, Perls TT, Andersen SL, Zmuda JM, Thyagarajan B, Yashin A, Wojczynski MK, Krinsky-McHale S, Handen BL, Christian BT, Head E, Mapstone ME, Schupf N, Lee JH, Barral S; Long‐Life Family Study; Alzheimer’s Disease Genetic Consortium; Alzheimer’s Biomarkers Consortium‐Down Syndrome. Alzheimers Dement. 2024 Apr; 20(4):2670-2679. Epub 2024 Feb 21. PMID: 38380866, DOI: 10.1002/alz.13718.

A trisomy 21-linked hematopoietic gene variant in microglia confers resilience in human iPSC models of Alzheimer’s disease. Jin M, Ma Z, Dang R, Zhang H, Kim R, Xue H, Pascual J, Finkbeiner S, Head E, Liu Y, Jiang P. bioRxiv [Preprint]. 2024 Mar 14:2024.03.12.584646. PMID: 38559257, DOI: 10.1101/2024.03.12.584646.

Down Syndrome Biobank Consortium: a perspective. Aldecoa I, Barroeta I, Carroll SL, Fortea J, Gilmore A, Ginsberg SD, Guzman SJ, Hamlett ED, Head E, Perez SE, Potter H, Molina-Porcel L, Raha-Chowdhury R, Wisniewski T, Yong WH, Zaman S, Ghosh S, Mufson EJ, Granholm AC. Alzheimers Dement. 2024 Mar; 20(3):2262-2272. Epub 2024 Jan 25. PMID: 38270275, DOI: 10.1002/alz.13692.

Neurofilament light chain concentration mediates the association between regional medial temporal lobe structure and memory in adults with Down syndrome. DiProspero N, Sathishkumar M, Janecek J, Smith A, McMillan L, Petersen M, Tustison N, Keator DB, Doran E, Hom CL, Nguyen D, Andrews H, Krinsky-McHale S, Brickman AM, Rosas HD, Lai F, Head E, Mapstone M, Silverman W, Lott IT, O’Bryant S, Yassa MA. Alzheimers Dement (Amst). 2024 Feb 12; 16(1):e12542. eCollection 2024 Jan-Mar. PMID: 38348178, DOI: 10.1002/dad2.12542.

Antibodies raised against an Aβ oligomer mimic recognize pathological features in Alzheimer’s disease and associated amyloid-disease brain tissue. Kreutzer AG, Parrocha CMT, Haerianardakani S, Guaglianone G, Nguyen JT, Diab MN, Yong W, Perez-Rosendahl M, Head E, Nowick JS. ACS Cent Sci. 2023 Dec 21; 10(1):104-121. eCollection 2024 Jan 24. PMID: 38292607, DOI: 10.1021/acscentsci.3c00592.

Plasma NT1-tau and Aβ₄₂ correlate with age and cognitive function in two large Down syndrome cohorts. Stern AM, Van Pelt KL, Liu L, Anderson AK, Ostaszewski B, Mapstone M, O’Bryant S, Petersen ME, Christian BT, Handen BL, Selkoe DJ, Schmitt F, Head E; Alzheimer’s Biomarker Consortium-Down Syndrome. Alzheimers Dement. 2023 Dec; 19(12):5755-5764. Epub 2023 Jul 12. PMID: 37438872, DOI: 10.1002/alz.13382.

Cerebrovascular disease is associated with Alzheimer’s plasma biomarker concentrations in adults with Down syndrome. Edwards NC, Lao PJ, Alshikho MJ, Ericsson OM, Rizvi B, Petersen ME, O’Bryant S, Aguilar LF, Simoes S, Mapstone M, Tudorascu DL, Janelidze S, Hansson O, Handen BL, Christian BT, Lee JH, Lai F, Rosas HD, Zaman S, Lott IT, Yassa MA, Gutierrez J, Wilcock DM, Head E, Brickman AM; Alzheimer’s Biomarkers Consortium–Down Syndrome. Brain Commun. 2024 Sep 25; 6(5):fcae331. PMID: 39403075, DOI: 10.1093/braincomms/fcae331.

Characterization of hippocampal sclerosis of aging and its association with other neuropathologic changes and cognitive deficits in the oldest-old. Sordo L, Qian T, Bukhari SA, Nguyen KM, Woodworth DC, Head E, Kawas CH, Corrada MM, Montine TJ, Sajjadi SA. Acta Neuropathol. 2023 Sep; 146(3):415-432. Epub 2023 Jun 29. PMID: 37382680, DOI: 10.1007/s00401-023-02606-9.

Enlarged perivascular spaces and plasma Aβ42/Aβ40 ratio in older adults without dementia. Kapoor A, Gaubert A, Yew B, Jang JY, Dutt S, Li Y, Alitin JPM, Nguyen A, Ho JK, Blanken AE, Sible IJ, Marshall A, Shenasa F, Rodgers KE, Martini AC, Head E, Nation DA. Neurobiol Aging. 2023 Aug; 128:43-48. Epub 2023 Apr 14. PMID: 37156179, DOI: 10.1016/j.neurobiolaging.2023.04.004.

Multimodal neuroimaging data from a 5-week heart rate variability biofeedback randomized clinical trial. Yoo HJ, Nashiro K, Min J, Cho C, Mercer N, Bachman SL, Nasseri P, Dutt S, Porat S, Choi P, Zhang Y, Grigoryan V, Feng T, Thayer JF, Lehrer P, Chang C, Stanley JA, Head E, Rouanet J, Marmarelis VZ, Narayanan S, Wisnowski J, Nation DA, Mather M. Sci Data. 2023 Jul 29; 10(1):503. PMID: 37516756, DOI: 10.1038/s41597-023-02396-5.

Timing of Alzheimer’s disease by intellectual disability level in Down syndrome. Hartley SL, Fleming V, Schworer EK, Peven J, Handen BL, Krinsky-McHale S, Hom C, Lee L, Tudorascu DL, Laymon C, Minhas D, Luo W, Cohen A, Zaman S, Ances BM, Mapstone M, Head E, Lai F, Rosas HD, Klunk W, Christian B; Alzheimer Biomarker Consortium-Down Syndrome. J Alzheimers Dis. 2023 Jul 17; 95(1):213-225. PMID: 37482997, DOI: 10.3233/JAD-230200.

Multi-ancestry genome-wide meta-analysis of 56,241 individuals identifies LRRC4C, LHX5-AS1 and nominates ancestry-specific loci PTPRK , GRB14 , and KIAA0825 as novel risk loci for Alzheimer’s disease: the Alzheimer’s Disease Genetics Consortium. Rajabli F, Benchek P, Tosto G, Kushch N, Sha J, Bazemore K, Zhu C, Lee WP, Haut J, Hamilton-Nelson KL, Wheeler NR, Zhao Y, Farrell JJ, Grunin MA, Leung YY, Kuksa PP, Li D, Lucio da Fonseca E, Mez JB, Palmer EL, Pillai J, Sherva RM, Song YE, Zhang X, Iqbal T, Pathak O, Valladares O, Kuzma AB, Abner E, Adams PM, Aguirre A, Albert MS, Albin RL, Allen M, Alvarez L, Apostolova LG, Arnold SE, Asthana S, Atwood CS, Ayres G, Baldwin CT, Barber RC, Barnes LL, Barral S, Beach TG, Becker JT, Beecham GW, Beekly D, Benitez BA, Bennett D, Bertelson J, Bird TD, Blacker D, Boeve BF, Bowen JD, Boxer A, Brewer J, Burke JR, Burns JM, Buxbaum JD, Cairns NJ, Cantwell LB, Cao C, Carlson CS, Carlsson CM, Carney RM, Carrasquillo MM, Chasse S, Chesselet MF, Chin NA, Chui HC, Chung J, Craft S, Crane PK, Cribbs DH, Crocco EA, Cruchaga C, Cuccaro ML, Cullum M, Darby E, Davis B, De Jager PL, DeCarli C, DeToledo J, Dick M, Dickson DW, Dombroski BA, Doody RS, Duara R, Ertekin-Taner N, Evans DA, Faber KM, Fairchild TJ, Fallon KB, Fardo DW, Farlow MR, Fernandez-Hernandez V, Ferris S, Foroud TM, Frosch MP, Fulton-Howard B, Galasko DR, Gamboa A, Gearing M, Geschwind DH, Ghetti B, Gilbert JR, Goate AM, Grabowski TJ, Graff-Radford NR, Green RC, Growdon JH, Hakonarson H, Hall J, Hamilton RL, Harari O, Hardy J, Harrell LE, Head E, Henderson VW, Hernandez M, Hohman T, Honig LS, Huebinger RM, Huentelman MJ, Hulette CM, Hyman BT, Hynan LS, Ibanez L, Jarvik GP, Jayadev S, Jin LW, Johnson K, Johnson L, Kamboh MI, Karydas AM, Katz MJ, Kauwe JS, Kaye JA, Keene CD, Khaleeq A, Kim R, Knebl J, Kowall NW, Kramer JH, Kukull WA, LaFerla FM, Lah JJ, Larson EB, Lerner A, Leverenz JB, Levey AI, Lieberman AP, Lipton RB, Logue M, Lopez OL, Lunetta KL, Lyketsos CG, Mains D, Margaret FE, Marson DC, Martin ERR, Martiniuk F, Mash DC, Masliah E, Massman P, Masurkar A, McCormick WC, McCurry SM, McDavid AN, McDonough S, McKee AC, Mesulam M, Miller BL, Miller CA, Miller JW, Montine TJ, Monuki ES, Morris JC, Mukherjee S, Myers AJ, Nguyen T, O’Bryant S, Olichney JM, Ory M, Palmer R, Parisi JE, Paulson HL, Pavlik V, Paydarfar D, Perez V, Peskind E, Petersen RC, Pierce A, Polk M, Poon WW, Potter H, Qu L, Quiceno M, Quinn JF, Raj A, Raskind M, Reiman EM, Reisberg B, Reisch JS, Ringman JM, Roberson ED, Rodriguear M, Rogaeva E, Rosen HJ, Rosenberg RN, Royall DR, Sager MA, Sano M, Saykin AJ, Schneider JA, Schneider LS, Seeley WW, Slifer SH, Small S, Smith AG, Smith JP, Sonnen JA, Spina S, St George-Hyslop P, Stern RA, Stevens AB, Strittmatter SM, Sultzer D, Swerdlow RH, Tanzi RE, Tilson JL, Trojanowski JQ, Troncoso JC, Tsuang DW, Van Deerlin VM, van Eldik LJ, Vance JM, Vardarajan BN, Vassar R, Vinters HV, Vonsattel JP, Weintraub S, Welsh-Bohmer KA, Whitehead PL, Wijsman EM, Wilhelmsen KC, Williams B, Williamson J, Wilms H, Wingo TS, Wisniewski T, Woltjer RL, Woon M, Wright CB, Wu CK, Younkin SG, Yu CE, Yu L, Zhu X, Kunkle BW, Bush WS, Wang LS, Farrer LA, Haines JL, Mayeux R, Pericak-Vance MA, Schellenberg GD, Jun GR, Reitz C, Naj AC. medRxiv [Preprint]. 2023 Jul 8:2023.07.06.23292311. PMID: 37461624, DOI: 10.1101/2023.07.06.23292311.

Amyloid futures in the expanding pathology of brain aging and dementia. Thorwald MA, Silva J, Head E, Finch CE. Alzheimers Dement. 2023 Jun; 19(6):2605-2617. Epub 2022 Dec 19. PMID: 36536382, DOI: 10.1002/alz.12896.

Reduced synaptic proteins and SNARE complexes in Down syndrome with Alzheimer’s disease and the Dp16 mouse Down syndrome model: impact of APP gene dose. Chen XQ, Zuo X, Becker A, Head E, Mobley WC. Alzheimers Dement. 2023 May; 19(5):2095-2116. Epub 2022 Nov 12. PMID: 36370135, DOI: 10.1002/alz.12835.

Differential involvement of hippocampal subfields in the relationship between Alzheimer’s pathology and memory interference in older adults. Adams JN, Márquez F, Larson MS, Janecek JT, Miranda BA, Noche JA, Taylor L, Hollearn MK, McMillan L, Keator DB, Head E, Rissman RA, Yassa MA. Alzheimers Dement (Amst). 2023 Apr 5; 15(2):e12419. eCollection 2023 Apr-Jun. PMID: 37035460, DOI: 10.1002/dad2.12419.

Increased plasma DYRK1A with aging may protect against neurodegenerative diseases. Delabar JM, Lagarde J, Fructuoso M, Mohammad A, Bottlaender M, Doran E, Lott I, Rivals I, Schmitt FA, Head E, Sarazin M, Potier MC. Transl Psychiatry. 2023 Apr 4; 13(1):111. PMID: 37015911, DOI: 10.1038/s41398-023-02419-0.

Innovating therapies for Down syndrome: an international virtual conference of the T21 Research Society. Hamlett ED, Flores-Aguilar L, Handen B, Potier MC, Granholm AC, Sherman S, Puig V, Santoro JD, Carmona-Iragui M, Rebillat AS, Head E, Strydom A, Busciglio J. Mol Syndromol. 2023 Apr; 14(2):89-100. Epub 2022 Nov 11. PMID: 37064334, DOI: 10.1159/000526021.

Modulating heart rate oscillation affects plasma amyloid beta and tau levels in younger and older adults. Min J, Rouanet J, Martini AC, Nashiro K, Yoo HJ, Porat S, Cho C, Wan J, Cole SW, Head E, Nation DA, Thayer JF, Mather M. Sci Rep. 2023 Mar 9; 13(1):3967. PMID: 36894565, DOI: 10.1038/s41598-023-30167-0.

Weight loss and Alzheimer’s disease in Down syndrome. Fleming V, Helsel BC, Ptomey LT, Rosas HD, Handen B, Laymon C, Christian BT, Head E, Mapstone M, Lai F, Krinsky-McHale S, Zaman S, Ances BM, Lee JH, Hartley SL; Alzheimer’s Biomarker Consortium — Down Syndrome. J Alzheimers Dis. 2023; 91(3):1215-1227. Epub 2022 Dec 19. PMID: 36565120, DOI: 10.3233/JAD-220865.

Comparison of amyloid burden in individuals with Down syndrome versus autosomal dominant Alzheimer’s disease: a cross-sectional study. Boerwinkle AH, Gordon BA, Wisch J, Flores S, Henson RL, Butt OH, McKay N, Chen CD, Benzinger TLS, Fagan AM, Handen BL, Christian BT, Head E, Mapstone M, Rafii MS, O’Bryant S, Lai F, Rosas HD, Lee JH, Silverman W, Brickman AM, Chhatwal JP, Cruchaga C, Perrin RJ, Xiong C, Hassenstab J, McDade E, Bateman RJ, Ances BM; Alzheimer’s Biomarker Consortium-Down Syndrome; Dominantly Inherited Alzheimer Network. Lancet Neurol. 2023 Jan; 22(1):55-65. ePub 2022 Dec 12. PMID: 36517172, DOI: 10.1016/S1474-4422(22)00408-2.

Aβ and tau prions feature in the neuropathogenesis of Down syndrome. Condello C, Maxwell AM, Castillo E, Aoyagi A, Graff C, Ingelsson M, Lannfelt L, Bird TD, Keene CD, Seeley WW, Perl DP, Head E, Prusiner SB. Proc Natl Acad Sci U S A. 2022 Nov 16; 119(46):e2212954119. Epub 2022 Nov 7. PMID: 36343257, DOI: 10.1073/pnas.2212954119.

Blood pressure variability and plasma Alzheimer’s disease biomarkers in older adults. Sible IJ, Yew B, Jang JY, Alitin JPM, Li Y, Gaubert A, Nguyen A, Dutt S, Blanken AE, Ho JK, Marshall AJ, Kapoor A, Shenasa F, Rodgers KE, Sturm VE, Head E, Martini A, Nation DA. Sci Rep. 2022 Oct 13; 12(1):17197. PMID: 36229634, DOI: 10.1038/s41598-022-20627-4.

Probing the proteome to explore potential correlates of increased Alzheimer’s-related cerebrovascular disease in adults with Down syndrome. Moni F, Petersen ME, Zhang F, Lao PJ, Zimmerman ME, Gu Y, Gutierrez J, Rizvi B, Laing KK, Igwe KC, Sathishkumar M, Keator D, Andrews H, Krinsky-McHale S, Head E, Lee JH, Lai F, Yassa MA, Rosas HD, Silverman W, Lott IT, Schupf N, O’Bryant S, Brickman AM. Alzheimers Dement. 2022 Oct; 18(10):1744-1753. Epub 2022 Feb 24. PMID: 35212182, DOI: 10.1002/alz.12627.

Exploring the role of sex differences in Alzheimer’s disease pathogenesis in Down syndrome. Andrews EJ, Martini AC, Head E. Front Neurosci. 2022 Aug 12; 16:954999. eCollection 2022. PMID: 36033603, DOI: 10.3389/fnins.2022.954999.

Type-I-interferon signaling drives microglial dysfunction and senescence in human iPSC models of Down syndrome and Alzheimer’s disease. Jin M, Xu R, Wang L, Alam MM, Ma Z, Zhu S, Martini AC, Jadali A, Bernabucci M, Xie P, Kwan KY, Pang ZP, Head E, Liu Y, Hart RP, Jiang P. Cell Stem Cell. 2022 Jul 7; 29(7):1135-1153.e8. PMID: 35803230, DOI: 10.1016/j.stem.2022.06.007.

Beyond amyloid: Immune, cerebrovascular, and metabolic contributions to Alzheimer disease in people with Down syndrome. Martini AC, Gross TJ, Head E, Mapstone M. Neuron. 2022 Jul 6; 110(13):2063-2079. Epub 2022 Apr 25. PMID: 35472307, DOI: 10.1016/j.neuron.2022.04.001.

Commentary on Oeckl et al., “Serum beta-synuclein is higher in Down syndrome and precedes rise of pTau181”. Head E, Zetterberg H. Ann Neurol. 2022 Jul; 92(1):3-5. Epub 2022 Jun 2. PMID: 35599543, DOI: 10.1002/ana.26414.

Impact of the COVID-19 pandemic on daily life, mood, and behavior of adults with Down syndrome. Hartley SL, Fleming V, Piro-Gambetti B, Cohen A, Ances BM, Yassa MA, Brickman AM, Handen BL, Head E, Mapstone M, Christian BT, Lott IT, Doran E, Zaman S, Krinsky-McHale S, Schmitt FA, Hom C, Schupf N; ABC-DS Group. Disabil Health J. 2022 Jul; 15(3):101278. Epub 2022 Feb 17. PMID: 35256308, DOI: 10.1016/j.dhjo.2022.101278.

Cholesterol and matrisome pathways dysregulated in astrocytes and microglia. Tcw J, Qian L, Pipalia NH, Chao MJ, Liang SA, Shi Y, Jain BR, Bertelsen SE, Kapoor M, Marcora E, Sikora E, Andrews EJ, Martini AC, Karch CM, Head E, Holtzman DM, Zhang B, Wang M, Maxfield FR, Poon WW, Goate AM. Cell. 2022 Jun 23; 185(13):2213-2233.e25. PMID: 35750033, DOI: 10.1016/j.cell.2022.05.017.

Absence of microglia promotes diverse pathologies and early lethality in Alzheimer’s disease mice. Kiani Shabestari S, Morabito S, Danhash EP, McQuade A, Sanchez JR, Miyoshi E, Chadarevian JP, Claes C, Coburn MA, Hasselmann J, Hidalgo J, Tran KN, Martini AC, Chang Rothermich W, Pascual J, Head E, Hume DA, Pridans C, Davtyan H, Swarup V, Blurton-Jones M. Cell Rep. 2022 Jun 14; 39(11):110961. PMID: 35705056, DOI: 10.1016/j.celrep.2022.110961.

A retrotransposon storm marks clinical phenoconversion to late-onset Alzheimer’s disease. Macciardi F, Giulia Bacalini M, Miramontes R, Boattini A, Taccioli C, Modenini G, Malhas R, Anderlucci L, Gusev Y, Gross TJ, Padilla RM, Fiandaca MS, Head E, Guffanti G, Federoff HJ, Mapstone M. Geroscience. 2022 Jun; 44(3):1525-1550. Epub 2022 May 19. PMID: 35585302, DOI: 10.1007/s11357-022-00580-w.

Impact of increased APP gene dose in Down syndrome and the Dp16 mouse model. Sawa M, Overk C, Becker A, Derse D, Albay R, Weldy K, Salehi A, Beach TG, Doran E, Head E, Yu YE, Mobley WC. Alzheimers Dement. 2022 Jun; 18(6):1203-1234. Epub 2021 Nov 10. PMID: 34757693, DOI: 10.1002/alz.12463.

Joint-label fusion brain atlases for dementia research in Down syndrome. Queder N, Phelan MJ, Taylor L, Tustison N, Doran E, Hom C, Nguyen D, Lai F, Pulsifer M, Price J, Kreisl WC, Rosas HD, Krinsky-McHale S, Brickman AM, Yassa MA, Schupf N, Silverman W, Lott IT, Head E, Mapstone M, Keator DB; Alzheimer’s Biomarkers Consortium. Alzheimers Dement (Amst). 2022 May 25; 14(1):e12324. eCollection 2022. PMID: 35634535, DOI: 10.1002/dad2.12324.

Obstructive sleep apnea, cerebrovascular disease, and amyloid in older adults with Down syndrome across the Alzheimer’s continuum. Lao P, Zimmerman ME, Hartley SL, Gutierrez J, Keator D, Igwe KC, Laing KK, Cotton-Samuel D, Sathishkumar M, Moni F, Andrews H, Krinsky-McHale S, Head E, Lee JH, Lai F, Yassa MA, Diana Rosas H, Silverman W, Lott IT, Schupf N, Brickman AM. Sleep Adv. 2022 May 5; 3(1):zpac013. eCollection 2022. PMID: 35669316, DOI: 10.1093/sleepadvances/zpac013.

Conducting clinical trials in persons with Down syndrome: summary from the NIH INCLUDE Down syndrome clinical trials readiness working group. Baumer NT, Becker ML, Capone GT, Egan K, Fortea J, Handen BL, Head E, Hendrix JE, Litovsky RY, Strydom A, Tapia IE, Rafii MS. J Neurodev Disord. 2022 Mar 23; 14(1):22. PMID: 35321660, DOI: 10.1186/s11689-022-09435-z.

Primitive reflexes and dementia in adults With Down syndrome. Harp J, Koehl L, Van Pelt K, Head E, Jicha G, Robertson W, Lightner D, Lott I, Schmitt F. Neurol Clin Pract. 2022 Feb; 12(1):6-13. PMID: 36157622, DOI: 10.1212/CPJ.0000000000001135.

Selective impairment of long-range default mode network functional connectivity as a biomarker for preclinical Alzheimer’s disease in people with Down syndrome. DiProspero ND, Keator DB, Phelan M, van Erp TGM, Doran E, Powell DK, Van Pelt KL, Schmitt FA, Head E, Lott IT, Yassa MA. J Alzheimers Dis. 2022; 85(1):153-165. Epub 2021 Nov 11. PMID: 34776436, DOI: 10.3233/JAD-210572.

Identifying dementia in Down syndrome with the severe impairment battery, brief praxis test and dementia scale for people with learning disabilities. Wallace ER, Harp JP, Van Pelt KL, Koehl LM, Caban-Holt AM, Anderson-Mooney AJ, Jicha GA, Lightner DD, Robertson WC, Head E, Schmitt FA. J Intellect Disabil Res. 2021 Dec; 65(12):1085-1096. Epub 2021 Nov 16. PMID: 34786786, DOI: 10.1111/jir.12901.

Alzheimer’s disease associated with Down syndrome: a genetic form of dementia. Fortea J, Zaman SH, Hartley S, Rafii MS, Head E, Carmona-Iragui M. Lancet Neurol. 2021 Nov; 20(11):930-942. PMID: 34687637, DOI: 10.1016/S1474-4422(21)00245-3.

Cognitive and behavioral domains that reliably differentiate normal aging and dementia in Down syndrome. Harp JP, Koehl LM, Pelt KLV, Hom CL, Doran E, Head E, Lott IT, Schmitt FA. Brain Sci. 2021 Aug 25; 11(9):1128. PMID: 34573150, DOI: 10.3390/brainsci11091128.

Postmortem neocortical ³H-PiB binding and levels of unmodified and pyroglutamate Aβ in Down syndrome and sporadic Alzheimer’s disease. Pivtoraiko VN, Racic T, Abrahamson EE, Villemagne VL, Handen BL, Lott IT, Head E, Ikonomovic MD. Front Aging Neurosci. 2021 Aug 13; 13:728739. eCollection 2021. PMID: 34489686, DOI: 10.3389/fnagi.2021.728739.

APOE ε4 association with cognition and Alzheimer disease biomarkers in Down syndrome — implications for clinical trials and treatments for all. Lemere CA, Head E, Holtzman DM. JAMA Neurol. 2021 Aug 1; 78(8):913-915. PMID: 34228117, DOI: 10.1001/jamaneurol.2021.1649.

Diagnostic and prognostic performance and longitudinal changes in plasma neurofilament light chain concentrations in adults with Down syndrome: a cohort study. Carmona-Iragui M, Alcolea D, Barroeta I, Videla L, Muñoz L, Van Pelt KL, Schmitt FA, Lightner DD, Koehl LM, Jicha G, Sacco S, Mircher C, Pape SE, Hithersay R, Clare ICH, Holland AJ, Nübling G, Levin J, Zaman SH, Strydom A, Rebillat AS, Head E, Blesa R, Lleó A, Fortea J. Lancet Neurol. 2021 Aug; 20(8):605-614. Epub 2021 Jul 21. PMID: 34302785, DOI: 10.1016/S1474-4422(21)00129-0.

Single-nucleus chromatin accessibility and transcriptomic characterization of Alzheimer’s disease. Morabito S, Miyoshi E, Michael N, Shahin S, Martini AC, Head E, Silva J, Leavy K, Perez-Rosendahl M, Swarup V. Nat Genet. 2021 Aug; 53(8):1143-1155. Epub 2021 Jul 8. PMID: 34239132, DOI: 10.1038/s41588-021-00894-z.

Tacrolimus protects against age-associated microstructural changes in the beagle brain. Radhakrishnan H, Ubele MF, Krumholz SM, Boaz K, Mefford JL, Jones ED, Meacham B, Smiley J, Puskás LG, Powell DK, Norris CM, Stark CEL, Head E. J Neurosci. 2021 Jun 9; 41(23):5124-5133. Epub 2021 May 5. PMID: 33952632, DOI: 10.1523/JNEUROSCI.0361-21.2021.

Neuropathology of aging in cats and its similarities to human Alzheimer’s disease. Sordo L, Martini AC, Houston EF, Head E, Gunn-Moore D. Front Aging. 2021 Jun 7; 2:684607. eCollection 2021. PMID: 35822024, DOI: 10.3389/fragi.2021.684607.

Markers of early changes in cognition across cohorts of adults with Down syndrome at risk of Alzheimer’s disease. Aschenbrenner AJ, Baksh RA, Benejam B, Beresford-Webb JA, Coppus A, Fortea J, Handen BL, Hartley S, Head E, Jaeger J, Levin J, Loosli SV, Rebillat AS, Sacco S, Schmitt FA, Thurlow KE, Zaman S, Hassenstab J, Strydom A. Alzheimers Dement (Amst). 2021 May 2; 13(1):e12184. eCollection 2021. PMID: 33969175, DOI: 10.1002/dad2.12184.

Cross-sectional exploration of plasma biomarkers of Alzheimer’s disease in Down syndrome: early data from the Longitudinal Investigation For Enhancing Down Syndrome Research (LIFE-DSR) study. Hendrix JA, Airey DC, Britton A, Burke AD, Capone GT, Chavez R, Chen J, Chicoine B, Costa ACS, Dage JL, Doran E, Esbensen A, Evans CL, Faber KM, Foroud TM, Hart S, Haugen K, Head E, Hendrix S, Hillerstrom H, Kishnani PS, Krell K, Ledesma DL, Lai F, Lott I, Ochoa-Lubinoff C, Mason J, Nicodemus-Johnson J, Proctor NK, Pulsifer MB, Revta C, Rosas HD, Rosser TC, Santoro S, Schafer K, Scheidemantel T, Schmitt F, Skotko BG, Stasko MR, Talboy A, Torres A, Wilmes K, Woodward J, Zimmer JA, Feldman HH, Mobley W. J Clin Med. 2021 Apr 28; 10(9):1907. PMID: 33924960, DOI: 10.3390/jcm10091907.

Opportunities, barriers, and recommendations in Down syndrome research. Hendrix JA, Amon A, Abbeduto L, Agiovlasitis S, Alsaied T, Anderson HA, Bain LJ, Baumer N, Bhattacharyya A, Bogunovic D, Botteron KN, Capone G, Chandan P, Chase I, Chicoine B, Cieuta-Walti C, DeRuisseau LR, Durand S, Esbensen A, Fortea J, Giménez S, Granholm AC, Hahn LJ, Head E, Hillerstrom H, Jacola LM, Janicki MP, Jasien JM, Kamer AR, Kent RD, Khor B, Lawrence JB, Lemonnier C, Lewanda AF, Mobley W, Moore PE, Nelson LP, Oreskovic NM, Osorio RS, Patterson D, Rasmussen SA, Reeves RH, Roizen N, Santoro S, Sherman SL, Talib N, Tapia IE, Walsh KM, Warren SF, White AN, Wong GW, Yi JS. Transl Sci Rare Dis. 2021; 5(3-4):99-129. Epub 2021 Apr 15. PMID: 34268067, DOI: 10.3233/trd-200090.

Plasma total-tau and neurofilament light chain as diagnostic biomarkers of Alzheimer’s disease dementia and mild cognitive impairment in adults with Down syndrome. Petersen ME, Rafii MS, Zhang F, Hall J, Julovich D, Ances BM, Schupf N, Krinsky-McHale SJ, Mapstone M, Silverman W, Lott I, Klunk W, Head E, Christian B, Foroud T, Lai F, Diana Rosas H, Zaman S, Wang MC, Tycko B, Lee JH, Handen B, Hartley S, Fortea J, O’Bryant S; Alzheimer’s Biomarker Consortium–Down Syndrome (ABC-DS). J Alzheimers Dis. 2021; 79(2):671-681. Epub 2020 Dec 16. PMID: 33337378, DOI: 10.3233/JAD-201167.

Chronic PERK induction promotes Alzheimer-like neuropathology in Down syndrome: insights for therapeutic intervention. Lanzillotta C, Zuliani I, Tramutola A, Barone E, Blarzino C, Folgiero V, Caforio M, Valentini D, Villani A, Locatelli F, Butterfield DA, Head E, Perluigi M, Abisambra JF, Di Domenico F. Prog Neurobiol. 2021 Jan; 196:101892. Epub 2020 Aug 11. PMID: 32795489, DOI: 10.1016/j.pneurobio.2020.101892.

Alzheimer-related cerebrovascular disease in Down syndrome. Lao PJ, Gutierrez J, Keator D, Rizvi B, Banerjee A, Igwe KC, Laing KK, Sathishkumar M, Moni F, Andrews H, Krinsky-McHale S, Head E, Lee JH, Lai F, Yassa MA, Rosas HD, Silverman W, Lott IT, Schupf N, Brickman AM. Ann Neurol. 2020 Dec; 88(6):1165-1177. Epub 2020 Oct 9. PMID: 32944999, DOI: 10.1002/ana.25905.

A preliminary study of cerebral blood flow, aging and dementia in people with Down syndrome. Thalman S, Van Pelt KL, Lin AL, Johnson NF, Jicha G, Caban-Holt A, Robertson W, Lightner D, Powell D, Head E, Schmitt F. J Intellect Disabil Res. 2020 Dec; 64(12):934-945. Epub 2020 Sep 30. PMID: 32996650, DOI: 10.1111/jir.12784.

Longitudinal assessment of dementia measures in Down syndrome. Koehl L, Harp J, Van Pelt KL, Head E, Schmitt FA. Alzheimers Dement (Amst). 2020 Nov 14; 12(1):e12075. eCollection 2020. PMID: 33225040, DOI: 10.1002/dad2.12075.

The AT(N) framework for Alzheimer’s disease in adults with Down syndrome. Rafii MS, Ances BM, Schupf N, Krinsky-McHale SJ, Mapstone M, Silverman W, Lott I, Klunk W, Head E, Christian B, Lai F, Rosas HD, Zaman S, Petersen ME, Strydom A, Fortea J, Handen B, O’Bryant S. Alzheimers Dement (Amst). 2020 Oct 27; 12(1):e12062. eCollection 2020. PMID: 33134477, DOI: 10.1002/dad2.12062.

Distribution of microglial phenotypes as a function of age and Alzheimer’s disease neuropathology in the brains of people with Down syndrome. Martini AC, Helman AM, McCarty KL, Lott IT, Doran E, Schmitt FA, Head E. Alzheimers Dement (Amst). 2020 Oct 14; 12(1):e12113. eCollection 2020. PMID: 33088896, DOI: 10.1002/dad2.12113.

Feasibility of dual-task gait to estimate Alzheimer’s related cognitive decline in Down syndrome. Van Pelt KL, Koehl L, Caban-Holt A, Anderson-Mooney A, Head E, Schmitt FA. Alzheimers Dement (Amst). 2020 Aug 25; 12(1):e12092. eCollection 2020. PMID: 32875058, DOI: 10.1002/dad2.12092.

The Alzheimer’s Biomarker Consortium — Down Syndrome: rationale and methodology. Handen BL, Lott IT, Christian BT, Schupf N, OBryant S, Mapstone M, Fagan AM, Lee JH, Tudorascu D, Wang MC, Head E, Klunk W, Ances B, Lai F, Zaman S, Krinsky-McHale S, Brickman AM, Rosas HD, Cohen A, Andrews H, Hartley S, Silverman W; Alzheimer’s Biomarker Consortium‐Down Syndrome (ABC‐DS). Alzheimers Dement (Amst). 2020 Aug 3; 12(1):e12065. eCollection 2020. PMID: 32775597, DOI: 10.1002/dad2.12065.

Predictors of worsening neuropathy and neuropathic pain after 12 years in people with HIV. Ellis RJ, Diaz M, Sacktor N, Marra C, Collier AC, Clifford DB, Calcutt N, Fields JA, Heaton RK, Letendre SL; CNS Antiretroviral Therapy Effects Research (CHARTER) Study Group. Ann Clin Transl Neurol. 2020 Jul; 7(7):1166-1173. Epub 2020 Jul 3. PMID: 32619341, DOI: 10.1002/acn3.51097.

Further understanding the connection between Alzheimer’s disease and Down syndrome. Snyder HM, Bain LJ, Brickman AM, Carrillo MC, Esbensen AJ, Espinosa JM, Fernandez F, Fortea J, Hartley SL, Head E, Hendrix J, Kishnani PS, Lai F, Lao P, Lemere C, Mobley W, Mufson EJ, Potter H, Zaman SH, Granholm AC, Rosas HD, Strydom A, Whitten MS, Rafii MS. Alzheimers Dement. 2020 Jul; 16(7):1065-1077. Epub 2020 Jun 16. PMID: 32544310, DOI: 10.1002/alz.12112.

Proteomic profiles for Alzheimer’s disease and mild cognitive impairment among adults with Down syndrome spanning serum and plasma: An Alzheimer’s Biomarker Consortium — Down Syndrome (ABC-DS) study. Petersen ME, Zhang F, Schupf N, Krinsky-McHale SJ, Hall J, Mapstone M, Cheema A, Silverman W, Lott I, Rafii MS, Handen B, Klunk W, Head E, Christian B, Foroud T, Lai F, Rosas HD, Zaman S, Ances BM, Wang MC, Tycko B, Lee JH, O’Bryant S; Alzheimer’s Biomarker Consortium – Down Syndrome (ABC‐DS). Alzheimers Dement (Amst). 2020 Jun 30; 12(1):e12039. eCollection 2020. PMID: 32626817, DOI: 10.1002/dad2.12039.

Biomarkers in Down syndrome can help us understand Alzheimer’s disease. Head E, Ances B. Lancet. 2020 Jun 27; 395(10242):1951-1953. PMID: 32593327, DOI: 10.1016/S0140-6736(20)30916-8.

APOE genotype-dependent pharmacogenetic responses to rapamycin for preventing Alzheimer’s disease. Lin AL, Parikh I, Yanckello LM, White RS, Hartz AMS, Taylor CE, McCulloch SD, Thalman SW, Xia M, McCarty K, Ubele M, Head E, Hyder F, Sanganahalli BG. Neurobiol Dis. 2020 Jun; 139:104834. Epub 2020 Mar 12. PMID: 32173556, DOI: 10.1016/j.nbd.2020.104834.

Metabolic correlates of prevalent mild cognitive impairment and Alzheimer’s disease in adults with Down syndrome. Mapstone M, Gross TJ, Macciardi F, Cheema AK, Petersen M, Head E, Handen BL, Klunk WE, Christian BT, Silverman W, Lott IT, Schupf N; Alzheimer’s Biomarkers Consortium–Down Syndrome (ABC‐DS) Investigators. Alzheimers Dement (Amst). 2020 Apr 5; 12(1):e12028. eCollection 2020. PMID: 32258359, DOI: 10.1002/dad2.12028.

Brain insulin resistance triggers early onset Alzheimer disease in Down syndrome. Tramutola A, Lanzillotta C, Di Domenico F, Head E, Butterfield DA, Perluigi M, Barone E. Neurobiol Dis. 2020 Apr; 137:104772. Epub 2020 Jan 24. PMID: 31987911, DOI: 10.1016/j.nbd.2020.104772.

Brain-blood partition coefficient and cerebral blood flow in canines using calibrated short TR recovery (CaSTRR) correction method. Thalman SW, Powell DK, Ubele M, Norris CM, Head E, Lin AL. Front Neurosci. 2019 Nov 5; 13:1189. eCollection 2019. PMID: 31749679, DOI: 10.3389/fnins.2019.01189.

Assessing general cognitive and adaptive abilities in adults with Down syndrome: a systematic review. Hamburg S, Lowe B, Startin CM, Padilla C, Coppus A, Silverman W, Fortea J, Zaman S, Head E, Handen BL, Lott I, Song W, Strydom A. J Neurodev Disord. 2019 Aug 30; 11(1):20. PMID: 31470792, DOI: 10.1186/s11689-019-9279-8.

Alzheimer’s disease in aging Down syndrome. Cohen AD, Head E, Lee JH. Dev Neurobiol. 2019 Jul; 79(7):611-612. Epub 2019 Sep 23. PMID: 31545018, DOI: 10.1002/dneu.22717.

Plasma metabolites related to cellular energy metabolism are altered in adults with Down syndrome and Alzheimer’s disease. Gross TJ, Doran E, Cheema AK, Head E, Lott IT, Mapstone M. Dev Neurobiol. 2019 Jul; 79(7):622-638. Epub 2019 Aug 26. PMID: 31419370, DOI: 10.1002/dneu.22716.

Neuropathological correlates of amyloid PET imaging in Down syndrome. Abrahamson EE, Head E, Lott IT, Handen BL, Mufson EJ, Christian BT, Klunk WE, Ikonomovic MD. Dev Neurobiol. 2019 Jul; 79(7):750-766. Epub 2019 Aug 17. PMID: 31379087, DOI: 10.1002/dneu.22713.

Dementia in Down syndrome: unique insights for Alzheimer disease research. Lott IT, Head E. Nat Rev Neurol. 2019 Mar; 15(3):135-147. PMID: 30733618, DOI: 10.1038/s41582-018-0132-6.

Perspectives on ethnic and racial disparities in Alzheimer’s disease and related dementias: update and areas of immediate need. Babulal GM, Quiroz YT, Albensi BC, Arenaza-Urquijo E, Astell AJ, Babiloni C, Bahar-Fuchs A, Bell J, Bowman GL, Brickman AM, Chételat G, Ciro C, Cohen AD, Dilworth-Anderson P, Dodge HH, Dreux S, Edland S, Esbensen A, Evered L, Ewers M, Fargo KN, Fortea J, Gonzalez H, Gustafson DR, Head E, Hendrix JA, Hofer SM, Johnson LA, Jutten R, Kilborn K, Lanctôt KL, Manly JJ, Martins RN, Mielke MM, Morris MC, Murray ME, Oh ES, Parra MA, Rissman RA, Roe CM, Santos OA, Scarmeas N, Schneider LS, Schupf N, Sikkes S, Snyder HM, Sohrabi HR, Stern Y, Strydom A, Tang Y, Terrera GM, Teunissen C, Melo van Lent D, Weinborn M, Wesselman L, Wilcock DM, Zetterberg H, O’Bryant SE; International Society to Advance Alzheimer’s Research and Treatment, Alzheimer’s Association. Alzheimers Dement. 2019 Feb; 15(2):292-312. Epub 2018 Dec 13. PMID: 30555031, DOI: 10.1016/j.jalz.2018.09.009.

Microbleeds and cerebral amyloid angiopathy in the brains of people with Down syndrome with Alzheimer’s disease. Helman AM, Siever M, McCarty KL, Lott IT, Doran E, Abner EL, Schmitt FA, Head E. J Alzheimers Dis. 2019; 67(1):103-112. Epub 2018 Nov 15. PMID: 30452414, DOI: 10.3233/JAD-180589.

Paving the way for therapy: the second international conference of the trisomy 21 research society. Reeves RH, Delabar J, Potier MC, Bhattacharyya A, Head E, Lemere C, Dekker AD, De Deyn P, Caviedes P, Dierssen M, Busciglio J. Mol Syndromol. 2019 Jan; 9(6):279-286. Epub 2018 Oct 30. PMID: 30800043, DOI: 10.1159/000494231.

Biliverdin reductase-A impairment links brain insulin resistance with increased Aβ production in an animal model of aging: implications for Alzheimer disease. Triani F, Tramutola A, Di Domenico F, Sharma N, Butterfield DA, Head E, Perluigi M, Barone E. Biochim Biophys Acta Mol Basis Dis. 2018 Oct; 1864(10):3181-3194. Epub 2018 Jul 5. PMID: 29981845, DOI: 10.1016/j.bbadis.2018.07.005.

Analysis of shared heritability in common disorders of the brain. Brainstorm Consortium; Anttila V, Bulik-Sullivan B, Finucane HK, Walters RK, Bras J, Duncan L, Escott-Price V, Falcone GJ, Gormley P, Malik R, Patsopoulos NA, Ripke S, Wei Z, Yu D, Lee PH, Turley P, Grenier-Boley B, Chouraki V, Kamatani Y, Berr C, Letenneur L, Hannequin D, Amouyel P, Boland A, Deleuze JF, Duron E, Vardarajan BN, Reitz C, Goate AM, Huentelman MJ, Kamboh MI, Larson EB, Rogaeva E, St George-Hyslop P, Hakonarson H, Kukull WA, Farrer LA, Barnes LL, Beach TG, Demirci FY, Head E, Hulette CM, Jicha GA, Kauwe JSK, Kaye JA, Leverenz JB, Levey AI, Lieberman AP, Pankratz VS, Poon WW, Quinn JF, Saykin AJ, Schneider LS, Smith AG, Sonnen JA, Stern RA, Van Deerlin VM, Van Eldik LJ, Harold D, Russo G, Rubinsztein DC, Bayer A, Tsolaki M, Proitsi P, Fox NC, Hampel H, Owen MJ, Mead S, Passmore P, Morgan K, Nöthen MM, Rossor M, Lupton MK, Hoffmann P, Kornhuber J, Lawlor B, McQuillin A, Al-Chalabi A, Bis JC, Ruiz A, Boada M, Seshadri S, Beiser A, Rice K, van der Lee SJ, De Jager PL, Geschwind DH, Riemenschneider M, Riedel-Heller S, Rotter JI, Ransmayr G, Hyman BT, Cruchaga C, Alegret M, Winsvold B, Palta P, Farh KH, Cuenca-Leon E, Furlotte N, Kurth T, Ligthart L, Terwindt GM, Freilinger T, Ran C, Gordon SD, Borck G, Adams HHH, Lehtimäki T, Wedenoja J, Buring JE, Schürks M, Hrafnsdottir M, Hottenga JJ, Penninx B, Artto V, Kaunisto M, Vepsäläinen S, Martin NG, Montgomery GW, Kurki MI, Hämäläinen E, Huang H, Huang J, Sandor C, Webber C, Muller-Myhsok B, Schreiber S, Salomaa V, Loehrer E, Göbel H, Macaya A, Pozo-Rosich P, Hansen T, Werge T, Kaprio J, Metspalu A, Kubisch C, Ferrari MD, Belin AC, van den Maagdenberg AMJM, Zwart JA, Boomsma D, Eriksson N, Olesen J, Chasman DI, Nyholt DR, Avbersek A, Baum L, Berkovic S, Bradfield J, Buono RJ, Catarino CB, Cossette P, De Jonghe P, Depondt C, Dlugos D, Ferraro TN, French J, Hjalgrim H, Jamnadas-Khoda J, Kälviäinen R, Kunz WS, Lerche H, Leu C, Lindhout D, Lo W, Lowenstein D, McCormack M, Møller RS, Molloy A, Ng PW, Oliver K, Privitera M, Radtke R, Ruppert AK, Sander T, Schachter S, Schankin C, Scheffer I, Schoch S, Sisodiya SM, Smith P, Sperling M, Striano P, Surges R, Thomas GN, Visscher F, Whelan CD, Zara F, Heinzen EL, Marson A, Becker F, Stroink H, Zimprich F, Gasser T, Gibbs R, Heutink P, Martinez M, Morris HR, Sharma M, Ryten M, Mok KY, Pulit S, Bevan S, Holliday E, Attia J, Battey T, Boncoraglio G, Thijs V, Chen WM, Mitchell B, Rothwell P, Sharma P, Sudlow C, Vicente A, Markus H, Kourkoulis C, Pera J, Raffeld M, Silliman S, Boraska Perica V, Thornton LM, Huckins LM, William Rayner N, Lewis CM, Gratacos M, Rybakowski F, Keski-Rahkonen A, Raevuori A, Hudson JI, Reichborn-Kjennerud T, Monteleone P, Karwautz A, Mannik K, Baker JH, O’Toole JK, Trace SE, Davis OSP, Helder SG, Ehrlich S, Herpertz-Dahlmann B, Danner UN, van Elburg AA, Clementi M, Forzan M, Docampo E, Lissowska J, Hauser J, Tortorella A, Maj M, Gonidakis F, Tziouvas K, Papezova H, Yilmaz Z, Wagner G, Cohen-Woods S, Herms S, Julià A, Rabionet R, Dick DM, Ripatti S, Andreassen OA, Espeseth T, Lundervold AJ, Steen VM, Pinto D, Scherer SW, Aschauer H, Schosser A, Alfredsson L, Padyukov L, Halmi KA, Mitchell J, Strober M, Bergen AW, Kaye W, Szatkiewicz JP, Cormand B, Ramos-Quiroga JA, Sánchez-Mora C, Ribasés M, Casas M, Hervas A, Arranz MJ, Haavik J, Zayats T, Johansson S, Williams N, Dempfle A, Rothenberger A, Kuntsi J, Oades RD, Banaschewski T, Franke B, Buitelaar JK, Arias Vasquez A, Doyle AE, Reif A, Lesch KP, Freitag C, Rivero O, Palmason H, Romanos M, Langley K, Rietschel M, Witt SH, Dalsgaard S, Børglum AD, Waldman I, Wilmot B, Molly N, Bau CHD, Crosbie J, Schachar R, Loo SK, McGough JJ, Grevet EH, Medland SE, Robinson E, Weiss LA, Bacchelli E, Bailey A, Bal V, Battaglia A, Betancur C, Bolton P, Cantor R, Celestino-Soper P, Dawson G, De Rubeis S, Duque F, Green A, Klauck SM, Leboyer M, Levitt P, Maestrini E, Mane S, De-Luca DM, Parr J, Regan R, Reichenberg A, Sandin S, Vorstman J, Wassink T, Wijsman E, Cook E, Santangelo S, Delorme R, Rogé B, Magalhaes T, Arking D, Schulze TG, Thompson RC, Strohmaier J, Matthews K, Melle I, Morris D, Blackwood D, McIntosh A, Bergen SE, Schalling M, Jamain S, Maaser A, Fischer SB, Reinbold CS, Fullerton JM, Guzman-Parra J, Mayoral F, Schofield PR, Cichon S, Mühleisen TW, Degenhardt F, Schumacher J, Bauer M, Mitchell PB, Gershon ES, Rice J, Potash JB, Zandi PP, Craddock N, Ferrier IN, Alda M, Rouleau GA, Turecki G, Ophoff R, Pato C, Anjorin A, Stahl E, Leber M, Czerski PM, Cruceanu C, Jones IR, Posthuma D, Andlauer TFM, Forstner AJ, Streit F, Baune BT, Air T, Sinnamon G, Wray NR, MacIntyre DJ, Porteous D, Homuth G, Rivera M, Grove J, Middeldorp CM, Hickie I, Pergadia M, Mehta D, Smit JH, Jansen R, de Geus E, Dunn E, Li QS, Nauck M, Schoevers RA, Beekman AT, Knowles JA, Viktorin A, Arnold P, Barr CL, Bedoya-Berrio G, Bienvenu OJ, Brentani H, Burton C, Camarena B, Cappi C, Cath D, Cavallini M, Cusi D, Darrow S, Denys D, Derks EM, Dietrich A, Fernandez T, Figee M, Freimer N, Gerber G, Grados M, Greenberg E, Hanna GL, Hartmann A, Hirschtritt ME, Hoekstra PJ, Huang A, Huyser C, Illmann C, Jenike M, Kuperman S, Leventhal B, Lochner C, Lyon GJ, Macciardi F, Madruga-Garrido M, Malaty IA, Maras A, McGrath L, Miguel EC, Mir P, Nestadt G, Nicolini H, Okun MS, Pakstis A, Paschou P, Piacentini J, Pittenger C, Plessen K, Ramensky V, Ramos EM, Reus V, Richter MA, Riddle MA, Robertson MM, Roessner V, Rosário M, Samuels JF, Sandor P, Stein DJ, Tsetsos F, Van Nieuwerburgh F, Weatherall S, Wendland JR, Wolanczyk T, Worbe Y, Zai G, Goes FS, McLaughlin N, Nestadt PS, Grabe HJ, Depienne C, Konkashbaev A, Lanzagorta N, Valencia-Duarte A, Bramon E, Buccola N, Cahn W, Cairns M, Chong SA, Cohen D, Crespo-Facorro B, Crowley J, Davidson M, DeLisi L, Dinan T, Donohoe G, Drapeau E, Duan J, Haan L, Hougaard D, Karachanak-Yankova S, Khrunin A, Klovins J, Kučinskas V, Lee Chee Keong J, Limborska S, Loughland C, Lönnqvist J, Maher B, Mattheisen M, McDonald C, Murphy KC, Nenadic I, van Os J, Pantelis C, Pato M, Petryshen T, Quested D, Roussos P, Sanders AR, Schall U, Schwab SG, Sim K, So HC, Stögmann E, Subramaniam M, Toncheva D, Waddington J, Walters J, Weiser M, Cheng W, Cloninger R, Curtis D, Gejman PV, Henskens F, Mattingsdal M, Oh SY, Scott R, Webb B, Breen G, Churchhouse C, Bulik CM, Daly M, Dichgans M, Faraone SV, Guerreiro R, Holmans P, Kendler KS, Koeleman B, Mathews CA, Price A, Scharf J, Sklar P, Williams J, Wood NW, Cotsapas C, Palotie A, Smoller JW, Sullivan P, Rosand J, Corvin A, Neale BM, Schott JM, Anney R, Elia J, Grigoroiu-Serbanescu M, Edenberg HJ, Murray R. Science. 2018 Jun 22; 360(6395):eaap8757. PMID: 29930110, DOI: 10.1126/science.aap8757.

Metabolic and vascular imaging biomarkers in Down syndrome provide unique insights into brain aging and Alzheimer disease pathogenesis. Head E, Powell DK, Schmitt FA. Front Aging Neurosci. 2018 Jun 21; 10:191. eCollection 2018. PMID: 29977201, DOI: 10.3389/fnagi.2018.00191.

Excess synaptojanin 1 contributes to place cell dysfunction and memory deficits in the aging hippocampus in three types of Alzheimer’s disease. Miranda AM, Herman M, Cheng R, Nahmani E, Barrett G, Micevska E, Fontaine G, Potier MC, Head E, Schmitt FA, Lott IT, Jiménez-Velázquez IZ, Antonarakis SE, Di Paolo G, Lee JH, Hussaini SA, Marquer C. Cell Rep. 2018 Jun 5; 23(10):2967-2975. PMID: 29874583, DOI: 10.1016/j.celrep.2018.05.011.

Deposition of phosphorylated amyloid-β in brains of aged nonhuman primates and canines. Kumar S, Frost JL, Cotman CW, Head E, Palmour R, Lemere CA, Walter J. Brain Pathol. 2018 May; 28(3):427-430. PMID: 29740941, DOI: 10.1111/bpa.12573.

An aged canid with behavioral deficits exhibits blood and cerebrospinal fluid amyloid beta oligomers. Rusbridge C, Salguero FJ, David MA, Faller KME, Bras JT, Guerreiro RJ, Richard-Londt AC, Grainger D, Head E, Brandner SGP, Summers B, Hardy J, Tayebi M. Front Aging Neurosci. 2018 Jan 30; 10:7. eCollection 2018. PMID: 29441010, DOI: 10.3389/fnagi.2018.00007.

Down syndrome, beta-amyloid and neuroimaging. Head E, Helman AM, Powell D, Schmitt FA. Free Radic Biol Med. 2018 Jan; 114:102-109. Epub 2017 Sep 19. PMID: 28935420, DOI: 10.1016/j.freeradbiomed.2017.09.013.

mTOR in Down syndrome: role in Aß and tau neuropathology and transition to Alzheimer disease-like dementia. Di Domenico F, Tramutola A, Foppoli C, Head E, Perluigi M, Butterfield DA. Free Radic Biol Med. 2018 Jan; 114:94-101. Epub 2017 Aug 12. PMID: 28807816, DOI: 10.1016/j.freeradbiomed.2017.08.009.

Disturbance of redox homeostasis in Down syndrome: role of iron dysmetabolism. Barone E, Arena A, Head E, Butterfield DA, Perluigi M. Free Radic Biol Med. 2018 Jan; 114:84-93. Epub 2017 Jul 10. PMID: 28705658, DOI: 10.1016/j.freeradbiomed.2017.07.009.

Cerebrovascular pathology in Down syndrome and Alzheimer disease. Head E, Phelan MJ, Doran E, Kim RC, Poon WW, Schmitt FA, Lott IT. Acta Neuropathol Commun. 2017 Dec 1; 5(1):93. PMID: 29195510, DOI: 10.1186/s40478-017-0499-4.

Cerebral amyloid angiopathy in Down syndrome and sporadic and autosomal-dominant Alzheimer’s disease. Carmona-Iragui M, Balasa M, Benejam B, Alcolea D, Fernández S, Videla L, Sala I, Sánchez-Saudinós MB, Morenas-Rodriguez E, Ribosa-Nogué R, Illán-Gala I, Gonzalez-Ortiz S, Clarimón J, Schmitt F, Powell DK, Bosch B, Lladó A, Rafii MS, Head E, Molinuevo JL, Blesa R, Videla S, Lleó A, Sánchez-Valle R, Fortea J. Alzheimers Dement. 2017 Nov; 13(11):1251-1260. Epub 2017 Apr 29. PMID: 28463681, DOI: 10.1016/j.jalz.2017.03.007.

HNE-modified proteins in Down syndrome: involvement in development of Alzheimer disease neuropathology. Barone E, Head E, Butterfield DA, Perluigi M. Free Radic Biol Med. 2017 Oct; 111:262-269. Epub 2016 Nov 10. PMID: 27838436, DOI: 10.1016/j.freeradbiomed.2016.10.508.

Investigation of the safety of focused ultrasound-induced blood-brain barrier opening in a natural canine model of aging. O’Reilly MA, Jones RM, Barrett E, Schwab A, Head E, Hynynen K. Theranostics. 2017 Aug 22; 7(14):3573-3584. eCollection 2017. PMID: 28912896, DOI: 10.7150/thno.20621.

Down syndrome: age-dependence of PiB binding in postmortem frontal cortex across the lifespan. LeVine H 3rd, Spielmann HP, Matveev S, Cauvi FM, Murphy MP, Beckett TL, McCarty K, Lott IT, Doran E, Schmitt F, Head E. Neurobiol Aging. 2017 Jun; 54:163-169. Epub 2017 Mar 14. PMID: 28385551, DOI: 10.1016/j.neurobiolaging.2017.03.005.

Polyubiquitinylation profile in Down syndrome brain before and after the development of Alzheimer neuropathology. Tramutola A, Di Domenico F, Barone E, Arena A, Giorgi A, di Francesco L, Schininà ME, Coccia R, Head E, Butterfield DA, Perluigi M. Antioxid Redox Signal. 2017 Mar 1; 26(7):280-298. Epub 2016 Oct 26. PMID: 27627691, DOI: 10.1089/ars.2016.6686.

Translational models for vascular cognitive impairment: a review including larger species. Hainsworth AH, Allan SM, Boltze J, Cunningham C, Farris C, Head E, Ihara M, Isaacs JD, Kalaria RN, Lesnik Oberstein SA, Moss MB, Nitzsche B, Rosenberg GA, Rutten JW, Salkovic-Petrisic M, Troen AM. BMC Med. 2017 Jan 25; 15(1):16. PMID: 28118831, DOI: 10.1186/s12916-017-0793-9.

Down syndrome, partial trisomy 21, and absence of Alzheimer’s disease: the role of APP. Doran E, Keator D, Head E, Phelan MJ, Kim R, Totoiu M, Barrio JR, Small GW, Potkin SG, Lott IT. J Alzheimers Dis. 2017; 56(2):459-470. Epub 2016 Dec 9. PMID: 27983553, DOI: 10.3233/JAD-160836.

Aβ vaccination in combination with behavioral enrichment in aged beagles: effects on cognition, Aβ, and microhemorrhages. Davis PR, Giannini G, Rudolph K, Calloway N, Royer CM, Beckett TL, Murphy MP, Bresch F, Pagani D, Platt T, Wang X, Donovan AS, Sudduth TL, Lou W, Abner E, Kryscio R, Wilcock DM, Barrett EG, Head E. Neurobiol Aging. 2017 Jan; 49:86-99. Epub 2016 Sep 26. PMID: 27776266, DOI: 10.1016/j.neurobiolaging.2016.09.007.

Commentary: Building the older adult fall prevention movement — steps and lessons learned. Smith ML, Chaudhary S, Nieb S, Bayakly R, Graham K, Head E. Front Public Health. 2016 Dec 22; 4:277. eCollection 2016. PMID: 28066756, DOI: 10.3389/fpubh.2016.00277.

¹H-MRS metabolites in adults with Down syndrome: effects of dementia. Lin AL, Powell D, Caban-Holt A, Jicha G, Robertson W, Gold BT, Davis R, Abner E, Wilcock DM, Schmitt FA, Head E. Neuroimage Clin. 2016 Jun 2; 11:728-735. eCollection 2016. PMID: 27330972, DOI: 10.1016/j.nicl.2016.06.001.

Proteolytic cleavage of apolipoprotein E in the Down syndrome brain. Day RJ, McCarty KL, Ockerse KE, Head E, Rohn TT. Aging Dis. 2016 May 27; 7(3):267-77. eCollection 2016 May. PMID: 27330841, DOI: 10.14336/AD.2015.1020.

Cerebrovascular contributions to aging and Alzheimer’s disease in Down syndrome. Wilcock DM, Schmitt FA, Head E. Biochim Biophys Acta. 2016 May; 1862(5):909-14. Epub 2015 Nov 26. PMID: 26593849, DOI: 10.1016/j.bbadis.2015.11.007.

Network-driven plasma proteomics expose molecular changes in the Alzheimer’s brain. Jaeger PA, Lucin KM, Britschgi M, Vardarajan B, Huang RP, Kirby ED, Abbey R, Boeve BF, Boxer AL, Farrer LA, Finch N, Graff-Radford NR, Head E, Hofree M, Huang R, Johns H, Karydas A, Knopman DS, Loboda A, Masliah E, Narasimhan R, Petersen RC, Podtelezhnikov A, Pradhan S, Rademakers R, Sun CH, Younkin SG, Miller BL, Ideker T, Wyss-Coray T. Mol Neurodegener. 2016 Apr 26; 11:31. PMID: 27112350, DOI: 10.1186/s13024-016-0095-2.

Gait dyspraxia as a clinical marker of cognitive decline in Down syndrome: A review of theory and proposed mechanisms. Anderson-Mooney AJ, Schmitt FA, Head E, Lott IT, Heilman KM. Brain Cogn. 2016 Apr; 104:48-57. Epub 2016 Feb 27. PMID: 26930369, DOI: 10.1016/j.bandc.2016.02.007.

A novel liposomal nanoparticle for the imaging of amyloid plaque by magnetic resonance imaging. Tanifum EA, Ghaghada K, Vollert C, Head E, Eriksen JL, Annapragada A. J Alzheimers Dis. 2016 Mar 25; 52(2):731-45. PMID: 27031484, DOI: 10.3233/JAD-151124.

Activation of p53 in Down syndrome and in the Ts65Dn mouse brain is associated with a pro-apoptotic phenotype. Tramutola A, Pupo G, Di Domenico F, Barone E, Arena A, Lanzillotta C, Brokeaart D, Blarzino C, Head E, Butterfield DA, Perluigi M. J Alzheimers Dis. 2016 Mar 8; 52(1):359-371. PMID: 26967221, DOI: 10.3233/JAD-151105.

Pathology of the aging brain in domestic and laboratory animals, and animal models of human neurodegenerative diseases. Youssef SA, Capucchio MT, Rofina JE, Chambers JK, Uchida K, Nakayama H, Head E. Vet Pathol. 2016 Mar; 53(2):327-48. Epub 2016 Feb 11. PMID: 26869150, DOI: 10.1177/0300985815623997.

Differential effects of structural modifications on the competition of chalcones for the PIB amyloid imaging ligand-binding site in Alzheimer’s disease brain and synthetic Aβ fibrils. Fosso MY, McCarty K, Head E, Garneau-Tsodikova S, LeVine H 3rd. ACS Chem Neurosci. 2016 Feb 17; 7(2):171-6. Epub 2015 Dec 30. PMID: 26682772, DOI: 10.1021/acschemneuro.5b00266.

Aging in Down syndrome and the development of Alzheimer’s disease neuropathology. Head E, Lott IT, Wilcock DM, Lemere CA. Curr Alzheimer Res. 2016; 13(1):18-29. PMID: 26651341, DOI: 10.2174/1567205012666151020114607.

Down syndrome individuals with Alzheimer’s disease have a distinct neuroinflammatory phenotype compared to sporadic Alzheimer’s disease. Wilcock DM, Hurban J, Helman AM, Sudduth TL, McCarty KL, Beckett TL, Ferrell JC, Murphy MP, Abner EL, Schmitt FA, Head E. Neurobiol Aging. 2015 Sep; 36(9):2468-74. Epub 2015 May 30. PMID: 26103884, DOI: 10.1016/j.neurobiolaging.2015.05.016.

Rarity of the Alzheimer disease-protective APP A673T variant in the United States. Wang LS, Naj AC, Graham RR, Crane PK, Kunkle BW, Cruchaga C, Murcia JD, Cannon-Albright L, Baldwin CT, Zetterberg H, Blennow K, Kukull WA, Faber KM, Schupf N, Norton MC, Tschanz JT, Munger RG, Corcoran CD, Rogaeva E; Alzheimer’s Disease Genetics Consortium, National Institute on Aging-Late-Onset Alzheimer’s Disease Family, Lin CF, Dombroski BA, Cantwell LB, Partch A, Valladares O, Hakonarson H, St George-Hyslop P, Green RC, Goate AM, Foroud TM, Carney RM, Larson EB, Behrens TW, Kauwe JS, Haines JL, Farrer LA, Pericak-Vance MA, Mayeux R, Schellenberg GD, Albert MS, Albin RL, Apostolova LG, Arnold SE, Barber R, Barmada M, Barnes LL, Beach TG, Becker JT, Beecham GW, Beekly D, Bennett DA, Bigio EH, Bird TD, Blacker D, Boeve BF, Bowen JD, Boxer A, Burke JR, Buxbaum JD, Cairns NJ, Cao C, Carlson CS, Carroll SL, Chui HC, Clark DG, Cribbs DH, Crocco EA, DeCarli C, DeKosky ST, Demirci FY, Dick M, Dickson DW, Duara R, Ertekin-Taner N, Fallon KB, Farlow MR, Ferris S, Frosch MP, Galasko DR, Ganguli M, Gearing M, Geschwind DH, Ghetti B, Gilbert JR, Glass JD, Graff-Radford NR, Growdon JH, Hamilton RL, Hamilton-Nelson KL, Harrell LE, Head E, Honig LS, Hulette CM, Hyman BT, Jarvik GP, Jicha GA, Jin LW, Jun G, Jun G, Kamboh MI, Karydas A, Kaye JA, Kim R, Koo EH, Kowall NW, Kramer JH, LaFerla FM, Lah JJ, Leverenz JB, Levey AI, Li G, Lieberman AP, Lopez OL, Lunetta KL, Lyketsos CG, Mack WJ, Marson DC, Martin ER, Martiniuk F, Mash DC, Masliah E, McCormick WC, McCurry SM, McDavid AN, McKee AC, Mesulam WM, Miller BL, Miller CA, Miller JW, Montine TJ, Morris JC, Murrell JR, Olichney JM, Parisi JE, Perry W, Peskind E, Petersen RC, Pierce A, Poon WW, Potter H, Quinn JF, Raj A, Raskind M, Reiman EM, Reisberg B, Reitz C, Ringman JM, Roberson ED, Rosen HJ, Rosenberg RN, Sano M, Saykin AJ, Schneider JA, Schneider LS, Seeley WW, Smith AG, Sonnen JA, Spina S, Stern RA, Tanzi RE, Thornton-Wells TA, Trojanowski JQ, Troncoso JC, Tsuang DW, Van Deerlin VM, Van Eldik LJ, Vardarajan BN, Vinters HV, Vonsattel JP, Weintraub S, Welsh-Bohmer KA, Williamson J, Wishnek S, Woltjer RL, Wright CB, Younkin SG, Yu CE, Yu L. JAMA Neurol. 2015 Feb; 72(2):209-16. PMID: 25531812, DOI: 10.1001/jamaneurol.2014.2157.

Bach1 overexpression in Down syndrome correlates with the alteration of the HO-1/BVR-a system: insights for transition to Alzheimer’s disease. Di Domenico F, Pupo G, Mancuso C, Barone E, Paolini F, Arena A, Blarzino C, Schmitt FA, Head E, Butterfield DA, Perluigi M. J Alzheimers Dis. 2015; 44(4):1107-20. PMID: 25391381, DOI: 10.3233/JAD-141254.

Is apolipoprotein E4 an important risk factor for dementia in persons with Down syndrome? Rohn TT, McCarty KL, Love JE, Head E. J Parkinsons Dis Alzheimers Dis. 2014 Dec 8; 1(1):7. PMID: 25594074, DOI: 10.13188/2376-922x.1000004.

Alzheimer’s therapeutics targeting amyloid beta 1-42 oligomers II: Sigma-2/PGRMC1 receptors mediate Abeta 42 oligomer binding and synaptotoxicity. Izzo NJ, Xu J, Zeng C, Kirk MJ, Mozzoni K, Silky C, Rehak C, Yurko R, Look G, Rishton G, Safferstein H, Cruchaga C, Goate A, Cahill MA, Arancio O, Mach RH, Craven R, Head E, LeVine H 3rd, Spires-Jones TL, Catalano SM. PLoS One. 2014 Nov 12; 9(11):e111899. eCollection 2014. PMID: 25390692, DOI: 10.1371/journal.pone.0111899.

Aging in the canine and feline brain. Vite CH, Head E. Vet Clin North Am Small Anim Pract. 2014 Nov; 44(6):1113-29. Epub 2014 Nov 1. PMID: 25441628, DOI: 10.1016/j.cvsm.2014.07.008.

Effects of multiple genetic loci on age at onset in late-onset Alzheimer disease: a genome-wide association study. Naj AC, Jun G, Reitz C, Kunkle BW, Perry W, Park YS, Beecham GW, Rajbhandary RA, Hamilton-Nelson KL, Wang LS, Kauwe JS, Huentelman MJ, Myers AJ, Bird TD, Boeve BF, Baldwin CT, Jarvik GP, Crane PK, Rogaeva E, Barmada MM, Demirci FY, Cruchaga C, Kramer PL, Ertekin-Taner N, Hardy J, Graff-Radford NR, Green RC, Larson EB, St George-Hyslop PH, Buxbaum JD, Evans DA, Schneider JA, Lunetta KL, Kamboh MI, Saykin AJ, Reiman EM, De Jager PL, Bennett DA, Morris JC, Montine TJ, Goate AM, Blacker D, Tsuang DW, Hakonarson H, Kukull WA, Foroud TM, Martin ER, Haines JL, Mayeux RP, Farrer LA, Schellenberg GD, Pericak-Vance MA; Alzheimer Disease Genetics Consortium, Albert MS, Albin RL, Apostolova LG, Arnold SE, Barber R, Barnes LL, Beach TG, Becker JT, Beekly D, Bigio EH, Bowen JD, Boxer A, Burke JR, Cairns NJ, Cantwell LB, Cao C, Carlson CS, Carney RM, Carrasquillo MM, Carroll SL, Chui HC, Clark DG, Corneveaux J, Cribbs DH, Crocco EA, DeCarli C, DeKosky ST, Dick M, Dickson DW, Duara R, Faber KM, Fallon KB, Farlow MR, Ferris S, Frosch MP, Galasko DR, Ganguli M, Gearing M, Geschwind DH, Ghetti B, Gilbert JR, Glass JD, Growdon JH, Hamilton RL, Harrell LE, Head E, Honig LS, Hulette CM, Hyman BT, Jicha GA, Jin LW, Karydas A, Kaye JA, Kim R, Koo EH, Kowall NW, Kramer JH, LaFerla FM, Lah JJ, Leverenz JB, Levey AI, Li G, Lieberman AP, Lin CF, Lopez OL, Lyketsos CG, Mack WJ, Martiniuk F, Mash DC, Masliah E, McCormick WC, McCurry SM, McDavid AN, McKee AC, Mesulam M, Miller BL, Miller CA, Miller JW, Murrell JR, Olichney JM, Pankratz VS, Parisi JE, Paulson HL, Peskind E, Petersen RC, Pierce A, Poon WW, Potter H, Quinn JF, Raj A, Raskind M, Reisberg B, Ringman JM, Roberson ED, Rosen HJ, Rosenberg RN, Sano M, Schneider LS, Seeley WW, Smith AG, Sonnen JA, Spina S, Stern RA, Tanzi RE, Thornton-Wells TA, Trojanowski JQ, Troncoso JC, Valladares O, Van Deerlin VM, Van Eldik LJ, Vardarajan BN, Vinters HV, Vonsattel JP, Weintraub S, Welsh-Bohmer KA, Williamson J, Wishnek S, Woltjer RL, Wright CB, Younkin SG, Yu CE, Yu L. JAMA Neurol. 2014 Nov; 71(11):1394-404. PMID: 25199842, DOI: 10.1001/jamaneurol.2014.1491.

An investigation of the molecular mechanisms engaged before and after the development of Alzheimer disease neuropathology in Down syndrome: a proteomics approach. Cenini G, Fiorini A, Sultana R, Perluigi M, Cai J, Klein JB, Head E, Butterfield DA. Free Radic Biol Med. 2014 Nov; 76:89-95. Epub 2014 Aug 20. PMID: 25151119, DOI: 10.1016/j.freeradbiomed.2014.08.006.

Redox proteomics analysis to decipher the neurobiology of Alzheimer-like neurodegeneration: overlaps in Down’s syndrome and Alzheimer’s disease brain. Butterfield DA, Di Domenico F, Swomley AM, Head E, Perluigi M. Biochem J. 2014 Oct 15; 463(2):177-89. PMID: 25242166, DOI: 10.1042/BJ20140772.

Bridging integrator 1 (BIN1) protein expression increases in the Alzheimer’s disease brain and correlates with neurofibrillary tangle pathology. Holler CJ, Davis PR, Beckett TL, Platt TL, Webb RL, Head E, Murphy MP. J Alzheimers Dis. 2014 Oct 10; 42(4):1221-7. PMID: 25024306, DOI: 10.3233/JAD-132450.

Juvenile traumatic brain injury induces long-term perivascular matrix changes alongside amyloid-beta accumulation. Jullienne A, Roberts JM, Pop V, Paul Murphy M, Head E, Bix GJ, Badaut J. J Cereb Blood Flow Metab. 2014 Oct; 34(10):1637-45. Epub 2014 Jul 23. PMID: 25052558, DOI: 10.1038/jcbfm.2014.124.

Synaptophysin and synaptojanin-1 in Down syndrome are differentially affected by Alzheimer’s disease. Martin SB, Dowling AL, Lianekhammy J, Lott IT, Doran E, Murphy MP, Beckett TL, Schmitt FA, Head E. J Alzheimers Dis. 2014 Sep 16; 42(3):767-75. PMID: 24927707, DOI: 10.3233/JAD-140795.

Con: Are we ready to translate Alzheimer’s disease-modifying therapies to people with Down syndrome? Head E, Schmitt FA. Alzheimers Res Ther. 2014 Sep 12; 6(5-8):61. eCollection 2014. PMID: 25478026, DOI: 10.1186/s13195-014-0061-6.

Neuropathological role of PI3K/Akt/mTOR axis in Down syndrome brain. Perluigi M, Pupo G, Tramutola A, Cini C, Coccia R, Barone E, Head E, Butterfield DA, Di Domenico F. Biochim Biophys Acta. 2014 Jul; 1842(7):1144-53. Epub 2014 Apr 13. PMID: 24735980, DOI: 10.1016/j.bbadis.2014.04.007.

Frontal white matter integrity in adults with Down syndrome with and without dementia. Powell D, Caban-Holt A, Jicha G, Robertson W, Davis R, Gold BT, Schmitt FA, Head E. Neurobiol Aging. 2014 Jul; 35(7):1562-9. Epub 2014 Feb 4. PMID: 24582640, DOI: 10.1016/j.neurobiolaging.2014.01.137.

Redox proteomics analysis of HNE-modified proteins in Down syndrome brain: clues for understanding the development of Alzheimer disease. Di Domenico F, Pupo G, Tramutola A, Giorgi A, Schininà ME, Coccia R, Head E, Butterfield DA, Perluigi M. Free Radic Biol Med. 2014 Jun; 71:270-280. Epub 2014 Mar 25. PMID: 24675226, DOI: 10.1016/j.freeradbiomed.2014.03.027.

Potential therapeutic effects of statins in Alzheimer’s disease. Mancuso C, Head E, Barone E, Perluigi M, Preziosi P, Butterfield DA. Handbook of Neurotoxicity, 1st ed (Kostrzewa RM ed); Springer. 2014 Jun 4; pp 2339-2354. Epub 2014 Jan 1. ISBN: 978-1-4614-5835-7, DOI: 10.1007/978-1-4614-5836-4_171.

Prevention approaches in a preclinical canine model of Alzheimer’s disease: benefits and challenges. Davis PR, Head E. Front Pharmacol. 2014 Mar 21; 5:47. eCollection 2014. PMID: 24711794, DOI: 10.3389/fphar.2014.00047.

Autoimmune manifestations in the 3xTg-AD model of Alzheimer’s disease. Marchese M, Cowan D, Head E, Ma D, Karimi K, Ashthorpe V, Kapadia M, Zhao H, Davis P, Sakic B. J Alzheimers Dis. 2014 Jan 7; 39(1):191-210. PMID: 24150111, DOI: 10.3233/JAD-131490.

Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer’s disease. Lambert JC, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C, DeStafano AL, Bis JC, Beecham GW, Grenier-Boley B, Russo G, Thorton-Wells TA, Jones N, Smith AV, Chouraki V, Thomas C, Ikram MA, Zelenika D, Vardarajan BN, Kamatani Y, Lin CF, Gerrish A, Schmidt H, Kunkle B, Dunstan ML, Ruiz A, Bihoreau MT, Choi SH, Reitz C, Pasquier F, Cruchaga C, Craig D, Amin N, Berr C, Lopez OL, De Jager PL, Deramecourt V, Johnston JA, Evans D, Lovestone S, Letenneur L, Morón FJ, Rubinsztein DC, Eiriksdottir G, Sleegers K, Goate AM, Fiévet N, Huentelman MW, Gill M, Brown K, Kamboh MI, Keller L, Barberger-Gateau P, McGuiness B, Larson EB, Green R, Myers AJ, Dufouil C, Todd S, Wallon D, Love S, Rogaeva E, Gallacher J, St George-Hyslop P, Clarimon J, Lleo A, Bayer A, Tsuang DW, Yu L, Tsolaki M, Bossù P, Spalletta G, Proitsi P, Collinge J, Sorbi S, Sanchez-Garcia F, Fox NC, Hardy J, Deniz Naranjo MC, Bosco P, Clarke R, Brayne C, Galimberti D, Mancuso M, Matthews F, Moebus S, Mecocci P, Del Zompo M, Maier W, Hampel H, Pilotto A, Bullido M, Panza F, Caffarra P, Nacmias B, Gilbert JR, Mayhaus M, Lannefelt L, Hakonarson H, Pichler S, Carrasquillo MM, Ingelsson M, Beekly D, Alvarez V, Zou F, Valladares O, Younkin SG, Coto E, Hamilton-Nelson KL, Gu W, Razquin C, Pastor P, Mateo I, Owen MJ, Faber KM, Jonsson PV, Combarros O, O’Donovan MC, Cantwell LB, Soininen H, Blacker D, Mead S, Mosley TH Jr, Bennett DA, Harris TB, Fratiglioni L, Holmes C, de Bruijn RF, Passmore P, Montine TJ, Bettens K, Rotter JI, Brice A, Morgan K, Foroud TM, Kukull WA, Hannequin D, Powell JF, Nalls MA, Ritchie K, Lunetta KL, Kauwe JS, Boerwinkle E, Riemenschneider M, Boada M, Hiltuenen M, Martin ER, Schmidt R, Rujescu D, Wang LS, Dartigues JF, Mayeux R, Tzourio C, Hofman A, Nöthen MM, Graff C, Psaty BM, Jones L, Haines JL, Holmans PA, Lathrop M, Pericak-Vance MA, Launer LJ, Farrer LA, van Duijn CM, Van Broeckhoven C, Moskvina V, Seshadri S, Williams J, Schellenberg GD, Amouyel P; European Alzheimer’s Disease Initiative, Genetic and Environmental Risk in Alzheimer’s Disease, Alzheimer’s Disease Genetic Consortium, Cohorts for Heart and Aging Research in Genomic Epidemiology, Alpérovitch A, Boland A, Delépoine M, Dubois B, Duron E, Epelbaum J, Van Cauwenberghe C, Engelborghs S, Vandenberghe R, De Deyn PP, Ferri R, Romano C, Caltagirone C, Orfei MD, Ciaramella A, Scarpini E, Fenoglio C, Siciliano G, Bonuccelli U, Bagnoli S, Bracco L, Bessi V, Cecchetti R, Bastgiani P, Squassina A, Seripa D, Frank-García A, Sastre I, Blesa R, Alcolea D, Suárez-Clavet M, Sánchez-Juan P, Muñoz Fernandez C, Aladro Benito Y, Thonberg H, Forshell C, Lilus L, Kinhult-Ståhlbom A, Giedraitis V, Kilander L, Brundin RM, Concari L, Helisalmi S, Koivisto AM, Haapasalo A, Solfrizzi V, Frisardi V, Ott J, Carney RM, Mash DC, Albert MS, Albin RL, Apostolova LG, Arnold SE, Barmada MM, Barnes LL, Beach TG, Bigio EH, Bird TD, Boeve BF, Bowen JD, Boxer A, Burk JR, Cairns NJ, Cao C, Carlson CS, Carroll SL, Chibnik LB, Chui HC, Clark DG, Corneveaux J, Cribbs DG, DeCarli C, DeKosky ST, Demirci FY, Dick M, Dickson DW, Duara R, Ertekin-Taner N, Fallon KB, Farlow MR, Ferris S, Frosch MP, Galasko GR, Ganguli M, Gearing M, Geschwind DH, Ghetti B, Gilman S, Glass JD, Growdon JH, Hamilton RL, Harrell LE, Head E, Honig LS, Hulette CM, Hyman BT, Jarvik GP, Jicha GA, Jin LW, Karydas A, Kauwe JS, Kaye JA, Kim R, Koo EH, Kowall NW, Kramer JH, Kramer P, LaFerla FM, Lah JJ, Levernez JB, Levey AI, Li G, Lieberman AP, Lyketsos CG, Mack WJ, Marson DC, Martiniuk F, Masliah E, McCormick WC, McCurry SM, McDavid AN, McKee AC, Mesulam M, Miller BL, Miller CA, Miller JW, Morris JC, Murrell JR, Olichney JM, Pankratz VS, Parasi JE, Peskind E, Peterson RC, Pierce A, Poon WW, Potter H, Quinn JF, Raj A, Raskind M, Raiman EM, Reisberg B, Ringman JM, Roberson ED, Rosen HJ, Rosenberg RN, Sano M, Saykin AJ, Schneider JA, Schneider LS, Seely WW, Smith AG, Sonnen JA, Spina S, Stern RA, Tanzi RE, Trojanowski JQ, Troncoso JC, Van Deerlin VM, Van Eldik LJ, Vinters HV, Vonsattel JP, Weintraub S, Welsh-Bohmer KA, Williamson J, Woltjer RL, Yu CE, Barber R, Au R, Wolf PA, Beiser A, Debette S, Yang Q, Weinstein G, Johnson AD, Wang J, Uitterlinden AG, Rivadeneira F, Koudstgaal PJ, Longstreth WT Jr, Becker JT, Kuller LH, Lumley T, Rice K, Garcia M, Aspelund T, Marksteiner JJ, Dal-Bianco P, Töglhofer AM, Freudenberger P, Ransmayr G, Benke T, Toeglhofer AM, Bressler J, Breteler MM, Fornage M, Hernández I, Rosende Roca M, Ana Mauleón M, Alegrat M, RamÍrez-Lorca R, González-Perez A, Chapman J, Stretton A, Morgan A, Kehoe PG, Medway C, Lord J, Turton J, Hooper NM, Vardy E, Warren JD, Schott JM, Uphill J, Ryan N, Rossor M, Ben-Shlomo Y, Makrina D, Gkatzima O, Lupton M, Koutroumani M, Avramidou D, Germanou A, Jessen F, Riedel-Heller S, Dichgans M, Heun R, Kölsch H, Schürmann B, Herold C, Lacour A, Drichel D, Hoffman P, Kornhuber J, Gu W, Feulner T, van den Bussche H, Lawlor B, Lynch A, Mann D, Smith AD, Warden D, Wilcock G, Heuser I, Wiltgang J, Frölich L, Hüll M, Mayo K, Livingston G, Bass NJ, Gurling H, McQuillen A, Gwilliam R, Deloukas P, Al-Chalabi A, Shaw CE, Singleton AB, Guerreiro R, Jöckel KH, Klopp N, Wichmann HE, Dickson DW, Graff-Radford NR, Ma L, Bisceglio G, Fisher E, Warner N, Pickering-Brown S. Nat Genet. 2013 Dec; 45(12):1452-8. Epub 2013 Oct 27. PMID: 24162737, DOI: 10.1038/ng.2802.

TREM2 and neurodegenerative disease. Reitz C, Mayeux R; Alzheimer’s Disease Genetics Consortium, Albert MS, Albin RL, Apostolova LG, Arnold SE, Baldwin CT, Barber R, Barmada MM, Barnes LL, Beach TG, Beecham GW, Beekly D, Bennett DA, Bigio EH, Bird TD, Blacker D, Boeve BF, Bowen JD, Boxer A, Burke JR, Buxbaum JD, Byrd GS, Cai G, Cairns NJ, Cantwell LB, Cao C, Carlson CS, Carney RM, Carroll SL, Chui HC, Clark DG, Crane PK, Cribbs DH, Crocco EA, Cruchaga C, DeCarli C, DeKosky ST, Demirci F, Dick M, Ertekin-Taner N, Evans D, Faber KM, Fallin D, Fallon KB, Farrer LA, Farlow MR, Ferris S, Frosch MP, Foroud TM, Galasko DR, Ganguli M, Gearing M, Geschwind DH, Ghetti B, Gilbert JR, Gilman S, Glass JD, Go RC, Goate AM, Graff-Radford NR, Green RC, Griffith P, Growdon JH, Haines JL, Hakonarson H, Hall K, Hamilton RL, Hamilton-Nelson KL, Haroutunian V, Harrell LE, Head E, Hendrie H, Honig LS, Hulette CM, Hyman BT, De Jager PL, Jarvik GP, Jicha GA, Jin LW, Jun G, Kamboh M, Karydas A, Kauwe JS, Kaye JA, Kim R, Koo EH, Kowall NW, Kramer JH, Kramer P, Kukull WA, LaFerla FM, Lah JJ, Lang-Walker R, Larson EB, Leverenz JB, Levey AI, Li G, Lieberman AP, Lin CF, Logue M, Lopez OL, Lunetta KL, Lyketsos CG, Mack WJ, Manly JJ, Marson DC, Martin ER, Martiniuk F, Mash DC, Masliah E, McCormick WC, McCurry SM, McDavid AN, McKee AC, Mesulam M, Miller BL, Miller CA, Miller JW, Montine TJ, Morris JC, Murrell JR, Naj A, Obisesan TO, Olichney JM, Parisi JE, Pericak-Vance MA, Peskind E, Petersen RC, Pierce A, Poon WW, Potter H, Quinn JF, Raj A, Raj T, Rajbhandary R, Raskind M, Reiman EM, Reisberg B, Ringman JM, Roberson ED, Rosen HJ, Rosenberg RN, Sano M, Saykin AJ, Schellenberg GD, Schneider JA, Schneider LS, Seeley WW, Smith AG, Sonnen JA, Spina S, Stern RA, Tanzi RE, Trojanowski JQ, Troncoso JC, Tsuang DW, Van Deerlin VM, Van Eldik LJ, Vardarajan BN, Vinters HV, Vonsattel JP, Valladares O, Wang LS, Weintraub S, Welsh-Bohmer KA, Williamson J, Woltjer RL, Wright CB, Younkin SG, Yu CE, Yu L. N Engl J Med. 2013 Oct 17; 369(16):1564-5. PMID: 24131184, DOI: 10.1056/NEJMc1306509.

A canine model of human aging and Alzheimer’s disease. Head E. Biochim Biophys Acta. 2013 Sep; 1832(9):1384-9. Epub 2013 Mar 23. PMID: 23528711, DOI: 10.1016/j.bbadis.2013.03.016.

Unusual features in four canine meningiomas. Schöniger S, Woolford L, Jutras L, Head E, de Lahunta A, Summers BA. J Comp Pathol. 2013 Aug-Oct; 149(2-3):237-41. Epub 2013 May 6. PMID: 23660088, DOI: 10.1016/j.jcpa.2013.03.003.

Impairment of proteostasis network in Down syndrome prior to the development of Alzheimer’s disease neuropathology: redox proteomics analysis of human brain. Di Domenico F, Coccia R, Cocciolo A, Murphy MP, Cenini G, Head E, Butterfield DA, Giorgi A, Schinina ME, Mancuso C, Cini C, Perluigi M. Biochim Biophys Acta. 2013 Aug; 1832(8):1249-59. Epub 2013 Apr 18. PMID: 23603808, DOI: 10.1016/j.bbadis.2013.04.013.

Variants in the ATP-binding cassette transporter (ABCA7), apolipoprotein E ϵ4,and the risk of late-onset Alzheimer disease in African Americans. Reitz C, Jun G, Naj A, Rajbhandary R, Vardarajan BN, Wang LS, Valladares O, Lin CF, Larson EB, Graff-Radford NR, Evans D, De Jager PL, Crane PK, Buxbaum JD, Murrell JR, Raj T, Ertekin-Taner N, Logue M, Baldwin CT, Green RC, Barnes LL, Cantwell LB, Fallin MD, Go RC, Griffith P, Obisesan TO, Manly JJ, Lunetta KL, Kamboh MI, Lopez OL, Bennett DA, Hendrie H, Hall KS, Goate AM, Byrd GS, Kukull WA, Foroud TM, Haines JL, Farrer LA, Pericak-Vance MA, Schellenberg GD, Mayeux R; Alzheimer Disease Genetics Consortium, Albert MS, Albin RL, Apostolova LG, Arnold SE, Barber R, Barmada MM, Beach TG, Beecham GW, Beekly D, Bigio EH, Bird TD, Blacker D, Boeve BF, Bowen JD, Boxer A, Burke JR, Cai G, Cairns NJ, Cao C, Carlson CS, Carney RM, Carroll SL, Chui HC, Clark DG, Cribbs DH, Crocco EA, Cruchaga C, DeCarli C, DeKosky ST, Demirci F, Dick M, Faber KM, Fallon KB, Farlow MR, Ferris S, Frosch MP, Galasko DR, Ganguli M, Gearing M, Geschwind DH, Ghetti B, Gilbert JR, Gilman S, Glass JD, Growdon JH, Hakonarson H, Hamilton RL, Hamilton-Nelson KL, Haroutunian V, Harrell LE, Head E, Honig LS, Hulette CM, Hyman BT, Jarvik GP, Jicha GA, Jin LW, Karydas A, Kauwe JS, Kaye JA, Kim R, Koo EH, Kowall NW, Kramer JH, Kramer P, LaFerla FM, Lah JJ, Lang-Walker R, Leverenz JB, Levey AI, Li G, Lieberman AP, Lyketsos CG, Mack WJ, Marson DC, Martin ER, Martiniuk F, Mash DC, Masliah E, McCormick WC, McCurry SM, McDavid AN, McKee AC, Mesulam M, Miller BL, Miller CA, Miller JW, Montine TJ, Morris JC, Olichney JM, Parisi JE, Peskind E, Petersen RC, Pierce A, Poon WW, Potter H, Quinn JF, Raj A, Raskind M, Reiman EM, Reisberg B, Ringman JM, Roberson ED, Rosen HJ, Rosenberg RN, Sano M, Saykin AJ, Schneider JA, Schneider LS, Seeley WW, Smith AG, Sonnen JA, Spina S, Stern RA, Tanzi RE, Trojanowski JQ, Troncoso JC, Tsuang DW, Van Deerlin VM, Van Eldik LJ, Vinters HV, Vonsattel JP, Weintraub S, Welsh-Bohmer KA, Williamson J, Woltjer RL, Wright CB, Younkin SG, Yu CE, Yu L. JAMA. 2013 Apr 10; 309(14):1483-92. PMID: 23571587, DOI: 10.1001/jama.2013.2973.

SORL1 is genetically associated with late-onset Alzheimer’s disease in Japanese, Koreans and Caucasians. Miyashita A, Koike A, Jun G, Wang LS, Takahashi S, Matsubara E, Kawarabayashi T, Shoji M, Tomita N, Arai H, Asada T, Harigaya Y, Ikeda M, Amari M, Hanyu H, Higuchi S, Ikeuchi T, Nishizawa M, Suga M, Kawase Y, Akatsu H, Kosaka K, Yamamoto T, Imagawa M, Hamaguchi T, Yamada M, Morihara T, Takeda M, Takao T, Nakata K, Fujisawa Y, Sasaki K, Watanabe K, Nakashima K, Urakami K, Ooya T, Takahashi M, Yuzuriha T, Serikawa K, Yoshimoto S, Nakagawa R, Kim JW, Ki CS, Won HH, Na DL, Seo SW, Mook-Jung I, St George-Hyslop P, Mayeux R, Haines JL, Pericak-Vance MA, Yoshida M, Nishida N, Tokunaga K, Yamamoto K, Tsuji S, Kanazawa I, Ihara Y, Schellenberg GD, Farrer LA, Kuwano R; Alzheimer Disease Genetics Consortium, Albert MS, Albin RL, Apostolova LG, Arnold SE, Baldwin CT, Barber R, Barmada MM, Barnes LL, Beach TG, Beecham GW, Beekly D, Bennett DA, Bigio EH, Bird TD, Blacker D, Boeve BF, Bowen JD, Boxer A, Burke JR, Buxbaum JD, Cairns NJ, Cantwell LB, Cao C, Carlson CS, Carney RM, Carrasquillo MM, Carroll SL, Chui HC, Clark DG, Corneveaux J, Crane PK, Cribbs DH, Crocco EA, Cruchaga C, De Jager PL, DeCarli C, DeKosky ST, Demirci F, Dick M, Dickson DW, Duara R, Ertekin-Taner N, Evans D, Faber KM, Fallon KB, Farlow MR, Ferris S, Foroud TM, Frosch MP, Galasko DR, Ganguli M, Gearing M, Geschwind DH, Ghetti B, Gilbert JR, Gilman S, Glass JD, Goate AM, Graff-Radford NR, Green RC, Growdon JH, Hakonarson H, Hamilton-Nelson KL, Hamilton RL, Hardy J, Harrell LE, Head E, Honig LS, Huentelman MJ, Hulette CM, Hyman BT, Jarvik GP, Jicha GA, Jin LW, Kamboh M, Karydas A, Kauwe JS, Kaye JA, Kim R, Koo EH, Kowall NW, Kramer JH, Kramer P, Kukull WA, LaFerla FM, Lah JJ, Larson EB, Leverenz JB, Levey AI, Li G, Lin CF, Lieberman AP, Lopez OL, Lunetta KL, Lyketsos CG, Mack WJ, Marson DC, Martin ER, Martiniuk F, Mash DC, Masliah E, McCormick WC, McCurry SM, McDavid AN, McKee AC, Mesulam M, Miller BL, Miller CA, Miller JW, Montine TJ, Morris JC, Murrell JR, Myers AJ, Naj AC, Olichney JM, Pankratz VS, Parisi JE, Peskind E, Petersen RC, Pierce A, Poon WW, Potter H, Quinn JF, Raj A, Rajbhandary RA, Raskind M, Reiman EM, Reisberg B, Reitz C, Ringman JM, Roberson ED, Rogaeva E, Rosen HJ, Rosenberg RN, Sano M, Saykin AJ, Schneider JA, Schneider LS, Seeley WW, Smith AG, Sonnen JA, Spina S, Stern RA, Tanzi RE, Trojanowski JQ, Troncoso JC, Tsuang DW, Valladares O, Van Deerlin VM, Van Eldik LJ, Vardarajan BN, Vinters HV, Vonsattel JP, Weintraub S, Welsh-Bohmer KA, Williamson J, Woltjer RL, Wright CB, Younkin SG, Yu CE, Yu L. PLoS One. 2013; 8(4):e58618. Epub 2013 Apr 2. Erratum in: PLoS One 2013; 8(7). PMID: 23565137, DOI: 10.1371/journal.pone.0058618.

Initial assessment of the pathogenic mechanisms of the recently identified Alzheimer risk loci. Holton P, Ryten M, Nalls M, Trabzuni D, Weale ME, Hernandez D, Crehan H, Gibbs JR, Mayeux R, Haines JL, Farrer LA, Pericak-Vance MA, Schellenberg GD, Ramirez-Restrepo M, Engel A, Myers AJ, Corneveaux JJ, Huentelman MJ, Dillman A, Cookson MR, Reiman EM, Singleton A, Hardy J, Guerreiro R; Alzheimer’s Disease Genetics Consortium, Apostolova LG, Arnold SE, Baldwin CT, Barber R, Barmada MM, Beach TG, Beecham GW, Beekly D, Bennett DA, Bigio EH, Bird TD, Blacker D, Boeve BF, Bowen JD, Boxer A, Burke JR, Buros J, Buxbaum JD, Cairns NJ, Cantwell LB, Cao C, Carlson CS, Carney RM, Carasquillo MM, Carroll SL, Chui HC, Clark DG, Cotman CW, Crane PK, Crocco EA, Cruchaga C, Cummings JL, De Jager PL, DeCarli C, DeKosky ST, Demirci FY, Diaz-Arrastia R, Dick M, Dickson DW, Duara R, Ellis WG, Ertekin-Taner N, Evans D, Faber KM, Fallon KB, Farlow MR, Ferris S, Foroud TM, Frosch MP, Galasko DR, Ganguli M, Gearing M, Geschwind DH, Ghetti B, Gilbert JR, Gilman S, Giordani B, Glass JD, Goate AM, Green RC, Growden JH, Hakonarson H, Hamilton RL, Harrell LE, Head E, Honig LS, Hulette CM, Hyman BT, Jarvik GP, Jicha GA, Jin LW, Jun G, Kamboh MI, Karlawish J, Karydas A, Kauwe JS, Kaye JA, Kim R, Koo EH, Kowall NW, Kramer P, Kukull WA, Lah JJ, Larson EB, Levey AI, Lieberman AP, Lopez OL, Lunetta KL, Mack WJ, Marson DC, Martin ER, Martiniuk F, Mash DC, Masliah E, McCormick WC, McCurry SM, McDavid AN, McKee AC, Mesulam M, Miller BL, Miller CA, Miller JW, Montine TJ, Morris JC, Naj AC, Notwotny P, Parisi JE, Perskind E, Petersen RC, Poon WW, Potter H, Quinn JF, Raj A, Rajbhandary RA, Raskind M, Reisberg B, Reitz C, Ringman JM, Roberson ED, Rogaeva E, Rosenberg RN, Sano M, Saykin AJ, Schneider JA, Schneider LS, Seeley WW, Shelanski ML, Smith CD, Sonnen JA, Spina S, St George-Hyslop P, Stern RA, Tanzi RE, Trojanowski JQ, Troncoso JC, Tsuang DW, Valladares O, Van Deerlin VM, Vardarajan BN, Vinters HV, Vonsattel JP, Wang LS, Weintraub S, Welsh-Bohmer KA, Williamson J, Woltjer RL, Wright CB, Younkin SG. Ann Hum Genet. 2013 Mar; 77(2):85-105. Epub 2013 Jan 30. PMID: 23360175, DOI: 10.1111/ahg.12000.

Chromosome 21-derived microRNAs provide an etiological basis for aberrant protein expression in human down syndrome brains. Kuhn DE, Nuovo GJ, Terry AV Jr, Martin MM, Malana GE, Sansom SE, Pleister AP, Beck WD, Head E, Feldman DS, Elton TS. J Biol Chem. 2013 Feb 8; 288(6):4228. PMID: 23690060, DOI: 10.1074/jbc.A109.033407.

Early brain injury alters the blood-brain barrier phenotype in parallel with β-amyloid and cognitive changes in adulthood. Pop V, Sorensen DW, Kamper JE, Ajao DO, Murphy MP, Head E, Hartman RE, Badaut J. J Cereb Blood Flow Metab. 2013 Feb; 33(2):205-14. Epub 2012 Nov 14. PMID: 23149553, DOI: 10.1038/jcbfm.2012.154.

Bapineuzumab alters Aβ composition: implications for the amyloid cascade hypothesis and anti-amyloid immunotherapy. Roher AE, Cribbs DH, Kim RC, Maarouf CL, Whiteside CM, Kokjohn TA, Daugs ID, Head E, Liebsack C, Serrano G, Belden C, Sabbagh MN, Beach TG. PLoS One. 2013; 8(3):e59735. Epub 2013 Mar 21. PMID: 23555764, DOI: 10.1371/journal.pone.0059735.

Diet and brain aging: effects on cell and mitochondrial function and structure. Pocernich C, Butterfield DA, Head E. Bioactive Food as Dietary Interventions for the Aging Population (Watson RR, Preedy VR eds); Academic Press. 2013; ch 20, pp 249-262. Epub 2012 Oct 26. ISBN: 978-0-12-397155-5, DOI: B978-0-12-397155-5.00030-1.

Alzheimer’s disease in Down syndrome. Head E, Powell D, Gold BT, Schmitt FA. Eur J Neurodegener Dis. 2012 Dec; 1(3):353-363. PMID: 25285303, PMCID: PMC4184282, Link: vol.-1-n.-3-Dec-2012-compresso.

A combination cocktail improves spatial attention in a canine model of human aging and Alzheimer’s disease. Head E, Murphey HL, Dowling AL, McCarty KL, Bethel SR, Nitz JA, Pleiss M, Vanrooyen J, Grossheim M, Smiley JR, Murphy MP, Beckett TL, Pagani D, Bresch F, Hendrix C. J Alzheimers Dis. 2012 Nov 14; 32(4):1029-42. PMID: 22886019, DOI: 10.3233/JAD-2012-120937.

Atorvastatin treatment in a dog preclinical model of Alzheimer’s disease leads to up-regulation of haem oxygenase-1 and is associated with reduced oxidative stress in brain. Butterfield DA, Barone E, Di Domenico F, Cenini G, Sultana R, Murphy MP, Mancuso C, Head E. Int J Neuropsychopharmacol. 2012 Aug; 15(7):981-7. Epub 2011 Jul 18. PMID: 21767440, DOI: 10.1017/S1461145711001118.

An amyloid β₄₂-dependent deficit in anandamide mobilization is associated with cognitive dysfunction in Alzheimer’s disease. Jung KM, Astarita G, Yasar S, Vasilevko V, Cribbs DH, Head E, Cotman CW, Piomelli D. Neurobiol Aging. 2012 Aug; 33(8):1522-32. Epub 2011 May 4. PMID: 21546126, DOI: 10.1016/j.neurobiolaging.2011.03.012.

Aging and down syndrome. Head E, Silverman W, Patterson D, Lott IT. Curr Gerontol Geriatr Res. 2012; 2012:412536. Epub 2012 Jul 11. PMID: 22844278, DOI: 10.1155/2012/412536.

Sterol lipid metabolism in down syndrome revisited: down syndrome is associated with a selective reduction in serum brassicasterol levels. Tansley G, Holmes DT, Lütjohann D, Head E, Wellington CL. Curr Gerontol Geriatr Res. 2012; 2012:179318. Epub 2012 May 9. PMID: 22649448, DOI: 10.1155/2012/179318.

Antioxidants in the canine model of human aging. Dowling AL, Head E. Biochim Biophys Acta. 2012 May; 1822(5):685-9. Epub 2011 Oct 8. PMID: 22005070, DOI: 10.1016/j.bbadis.2011.09.020.

Frontal cortex neuropathology in dementia pugilistica. Saing T, Dick M, Nelson PT, Kim RC, Cribbs DH, Head E. J Neurotrauma. 2012 Apr 10; 29(6):1054-70. Epub 2012 Apr 10. PMID: 22017610, DOI: 10.1089/neu.2011.1957.

BDNF increases with behavioral enrichment and an antioxidant diet in the aged dog. Fahnestock M, Marchese M, Head E, Pop V, Michalski B, Milgram WN, Cotman CW. Neurobiol Aging. 2012 Mar; 33(3):546-54. Epub 2010 May 5. PMID: 20447733, DOI: 10.1016/j.neurobiolaging.2010.03.019.

Association between frontal cortex oxidative damage and beta-amyloid as a function of age in Down syndrome. Cenini G, Dowling AL, Beckett TL, Barone E, Mancuso C, Murphy MP, Levine H 3rd, Lott IT, Schmitt FA, Butterfield DA, Head E. Biochim Biophys Acta. 2012 Feb; 1822(2):130-8. Epub 2011 Oct 8. PMID: 22009041, DOI: 10.1016/j.bbadis.2011.10.001.

BACE2 expression increases in human neurodegenerative disease. Holler CJ, Webb RL, Laux AL, Beckett TL, Niedowicz DM, Ahmed RR, Liu Y, Simmons CR, Dowling AL, Spinelli A, Khurgel M, Estus S, Head E, Hersh LB, Murphy MP. Am J Pathol. 2012 Jan; 180(1):337-50. Epub 2011 Nov 7. PMID: 22074738, DOI: 10.1016/j.ajpath.2011.09.034.

Biliverdin reductase-A: a novel drug target for atorvastatin in a dog pre-clinical model of Alzheimer disease. Barone E, Mancuso C, Di Domenico F, Sultana R, Murphy MP, Head E, Butterfield DA. J Neurochem. 2012 Jan; 120(1):135-46. Epub 2011 Oct 17. PMID: 22004509, DOI: 10.1111/j.1471-4159.2011.07538.x.

Aβ aggregation profiles and shifts in APP processing favor amyloidogenesis in canines. Pop V, Head E, Berchtold NC, Glabe CG, Studzinski CM, Weidner AM, Murphy MP, Cotman CW. Neurobiol Aging. 2012 Jan; 33(1):108-20. Epub 2010 Apr 30. PMID: 20434811, DOI: 10.1016/j.neurobiolaging.2010.02.008.

Therapeutic interventions targeting Beta amyloid pathogenesis in an aging dog model. Martin SB, Dowling AL, Head E. Curr Neuropharmacol. 2011 Dec; 9(4):651-61. PMID: 22654723, DOI: 10.2174/157015911798376217.

Intersectin 1 contributes to phenotypes in vivo: implications for Down’s syndrome. Hunter MP, Nelson M, Kurzer M, Wang X, Kryscio RJ, Head E, Pinna G, O’Bryan JP. Neuroreport. 2011 Oct 26; 22(15):767-72. PMID: 21876463, DOI: 10.1097/WNR.0b013e32834ae348.

Elevated stearoyl-CoA desaturase in brains of patients with Alzheimer’s disease. Astarita G, Jung KM, Vasilevko V, Dipatrizio NV, Martin SK, Cribbs DH, Head E, Cotman CW, Piomelli D. PLoS One. 2011; 6(10):e24777. Epub 2011 Oct 26. PMID: 22046234, DOI: 10.1371/journal.pone.0024777.

Neurobiology of the aging dog. Head E. Age (Dordr). 2011 Sep; 33(3):485-96. Epub 2010 Sep 16. PMID: 20845082, DOI: 10.1007/s11357-010-9183-3.

Coenzyme Q10 and cognition in atorvastatin treated dogs. Martin SB, Cenini G, Barone E, Dowling AL, Mancuso C, Butterfield DA, Murphy MP, Head E. Neurosci Lett. 2011 Aug 26; 501(2):92-5. Epub 2011 Jul 8. PMID: 21763754, DOI: 10.1016/j.neulet.2011.06.054.

Impact of aging on brain structure and function in rodents and canines. Murphy MP, Head E. Fundamental Neuropathology for Pathologists and Toxicologists: Principles and Techniques (Bolon B, Butt MT eds); Wiley. 2011 Aug 19; ch 8, pp 125-138. ISBN: 978-0-4702-2733-6, DOI: 9780470939956.ch8.

Down syndrome and dementia: a randomized, controlled trial of antioxidant supplementation. Lott IT, Doran E, Nguyen VQ, Tournay A, Head E, Gillen DL. Am J Med Genet A. 2011 Aug; 155A(8):1939-48. Epub 2011 Jul 7. PMID: 21739598, DOI: 10.1002/ajmg.a.34114.

The canine model of human aging and disease. Cotman CW, Head E. Handbook of Animal Models in Alzheimer’s Disease (Casadesus G ed); IOS Press. 2011 Jun; ch 2, pp 15-38. Pub 2011 Jul 5. ISBN: 978-1-60750-732-1, DOI: 10.3233/978-1-60750-733-8-15, Link: vddRI_qV5_gC.

Alzheimer’s disease is not “brain aging”: neuropathological, genetic, and epidemiological human studies. Nelson PT, Head E, Schmitt FA, Davis PR, Neltner JH, Jicha GA, Abner EL, Smith CD, Van Eldik LJ, Kryscio RJ, Scheff SW. Acta Neuropathol. 2011 May; 121(5):571-87. Epub 2011 Apr 24. PMID: 21516511, DOI: 10.1007/s00401-011-0826-y.

Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer’s disease. Naj AC, Jun G, Beecham GW, Wang LS, Vardarajan BN, Buros J, Gallins PJ, Buxbaum JD, Jarvik GP, Crane PK, Larson EB, Bird TD, Boeve BF, Graff-Radford NR, De Jager PL, Evans D, Schneider JA, Carrasquillo MM, Ertekin-Taner N, Younkin SG, Cruchaga C, Kauwe JS, Nowotny P, Kramer P, Hardy J, Huentelman MJ, Myers AJ, Barmada MM, Demirci FY, Baldwin CT, Green RC, Rogaeva E, St George-Hyslop P, Arnold SE, Barber R, Beach T, Bigio EH, Bowen JD, Boxer A, Burke JR, Cairns NJ, Carlson CS, Carney RM, Carroll SL, Chui HC, Clark DG, Corneveaux J, Cotman CW, Cummings JL, DeCarli C, DeKosky ST, Diaz-Arrastia R, Dick M, Dickson DW, Ellis WG, Faber KM, Fallon KB, Farlow MR, Ferris S, Frosch MP, Galasko DR, Ganguli M, Gearing M, Geschwind DH, Ghetti B, Gilbert JR, Gilman S, Giordani B, Glass JD, Growdon JH, Hamilton RL, Harrell LE, Head E, Honig LS, Hulette CM, Hyman BT, Jicha GA, Jin LW, Johnson N, Karlawish J, Karydas A, Kaye JA, Kim R, Koo EH, Kowall NW, Lah JJ, Levey AI, Lieberman AP, Lopez OL, Mack WJ, Marson DC, Martiniuk F, Mash DC, Masliah E, McCormick WC, McCurry SM, McDavid AN, McKee AC, Mesulam M, Miller BL, Miller CA, Miller JW, Parisi JE, Perl DP, Peskind E, Petersen RC, Poon WW, Quinn JF, Rajbhandary RA, Raskind M, Reisberg B, Ringman JM, Roberson ED, Rosenberg RN, Sano M, Schneider LS, Seeley W, Shelanski ML, Slifer MA, Smith CD, Sonnen JA, Spina S, Stern RA, Tanzi RE, Trojanowski JQ, Troncoso JC, Van Deerlin VM, Vinters HV, Vonsattel JP, Weintraub S, Welsh-Bohmer KA, Williamson J, Woltjer RL, Cantwell LB, Dombroski BA, Beekly D, Lunetta KL, Martin ER, Kamboh MI, Saykin AJ, Reiman EM, Bennett DA, Morris JC, Montine TJ, Goate AM, Blacker D, Tsuang DW, Hakonarson H, Kukull WA, Foroud TM, Haines JL, Mayeux R, Pericak-Vance MA, Farrer LA, Schellenberg GD. Nat Genet. 2011 May; 43(5):436-41. Epub 2011 Apr 3. PMID: 21460841, DOI: 10.1038/ng.801.

Brain levels of sex steroid hormones in men and women during normal aging and in Alzheimer’s disease. Rosario ER, Chang L, Head EH, Stanczyk FZ, Pike CJ. Neurobiol Aging. 2011 Apr; 32(4):604-13. Epub 2009 May 9. PMID: 19428144, DOI: 10.1016/j.neurobiolaging.2009.04.008.

Long-term high-dose atorvastatin decreases brain oxidative and nitrosative stress in a preclinical model of Alzheimer disease: a novel mechanism of action. Barone E, Cenini G, Di Domenico F, Martin S, Sultana R, Mancuso C, Murphy MP, Head E, Butterfield DA. Pharmacol Res. 2011 Mar; 63(3):172-80. Epub 2010 Dec 27. PMID: 21193043, DOI: 10.1016/j.phrs.2010.12.007.

Plasma amyloid-β as a function of age, level of intellectual disability, and presence of dementia in Down syndrome. Head E, Doran E, Nistor M, Hill M, Schmitt FA, Haier RJ, Lott IT. J Alzheimers Dis. 2011 Feb 14; 23(3):399-409. PMID: 21116050, DOI: 10.3233/JAD-2010-101335.

Conformation dependent monoclonal antibodies distinguish different replicating strains or conformers of prefibrillar Aβ oligomers. Kayed R, Canto I, Breydo L, Rasool S, Lukacsovich T, Wu J, Albay R 3rd, Pensalfini A, Yeung S, Head E, Marsh JL, Glabe C. Mol Neurodegener. 2010 Dec 13; 5:57. PMID: 21144050, DOI: 10.1186/1750-1326-5-57.

Meta-analysis confirms CR1, CLU, and PICALM as Alzheimer disease risk loci and reveals interactions with APOE genotypes. Jun G, Naj AC, Beecham GW, Wang LS, Buros J, Gallins PJ, Buxbaum JD, Ertekin-Taner N, Fallin MD, Friedland R, Inzelberg R, Kramer P, Rogaeva E, St George-Hyslop P, Cantwell LB, Dombroski BA, Saykin AJ, Reiman EM, Bennett DA, Morris JC, Lunetta KL, Martin ER, Montine TJ, Goate AM, Blacker D, Tsuang DW, Beekly D, Cupples LA, Hakonarson H, Kukull W, Foroud TM, Haines J, Mayeux R, Farrer LA, Pericak-Vance MA, Schellenberg GD; Alzheimer’s Disease Genetics Consortium, Arnold SE, Baldwin CT, Barber R, Beach T, Bigio EH, Bird TD, Boxer A, Burke JR, Cairns N, Carroll SL, Chui HC, Clark DG, Cotman CW, Cummings JL, DeCarli C, Diaz-Arrastia R, Dick M, Dickson DW, Ellis WG, Fallon KB, Farlow MR, Ferris S, Frosch MP, Galasko DR, Gearing M, Geschwind DH, Ghetti B, Gilman S, Giordani B, Glass J, Graff-Radford NR, Green RC, Growdon JH, Hamilton RL, Harrell LE, Head E, Honig LS, Hulette CM, Hyman BT, Jicha GA, Jin LW, Johnson N, Karlawish J, Karydas A, Kaye JA, Kim R, Koo EM, Kowall NW, Lah JJ, Levey AI, Lieberman A, Lopez OL, Mack WJ, Markesbery W, Marson DC, Martiniuk F, Masliah E, McKee AC, Mesulam M, Miller JW, Miller BL, Miller CA, Parisi JE, Perl DP, Peskind E, Petersen RC, Poon W, Quinn JF, Raskind M, Reisberg B, Ringman JM, Roberson ED, Rosenberg RN, Sano M, Schneider JA, Schneider LS, Seeley W, Shelanski ML, Smith CD, Spina S, Stern RA, Tanzi RE, Trojanowski JQ, Troncoso JC, Van Deerlin VM, Vinters HV, Vonsattel JP, Weintraub S, Welsh-Bohmer KA, Woltjer RL, Younkin SG. Arch Neurol. 2010 Dec; 67(12):1473-84. Epub 2010 Aug 9. Erratum in: Arch Neurol. 2011 Feb;68(2):159. PMID: 20697030, DOI: 10.1001/archneurol.2010.201.

Aging and cerebrovascular dysfunction: contribution of hypertension, cerebral amyloid angiopathy, and immunotherapy. Vasilevko V, Passos GF, Quiring D, Head E, Kim RC, Fisher M, Cribbs DH. Ann N Y Acad Sci. 2010 Oct; 1207:58-70. PMID: 20955427, DOI: 10.1111/j.1749-6632.2010.05786.x.

Changes in cognition and amyloid-β processing with long term cholesterol reduction using atorvastatin in aged dogs. Murphy MP, Morales J, Beckett TL, Astarita G, Piomelli D, Weidner A, Studzinski CM, Dowling AL, Wang X, Levine H 3rd, Kryscio RJ, Lin Y, Barrett E, Head E. J Alzheimers Dis. 2010 Sep 28; 22(1):135-50. PMID: 20847439, DOI: 10.3233/JAD-2010-100639.

Deficient liver biosynthesis of docosahexaenoic acid correlates with cognitive impairment in Alzheimer’s disease. Astarita G, Jung KM, Berchtold NC, Nguyen VQ, Gillen DL, Head E, Cotman CW, Piomelli D. PLoS One. 2010 Sep 8; 5(9):e12538. PMID: 20838618, DOI: 10.1371/journal.pone.0012538.

Linear and conformation specific antibodies in aged beagles after prolonged vaccination with aggregated Abeta. Vasilevko V, Pop V, Kim HJ, Saing T, Glabe CC, Milton S, Barrett EG, Cotman CW, Cribbs DH, Head E. Neurobiol Dis. 2010 Sep; 39(3):301-10. Epub 2010 May 6. PMID: 20451612, DOI: 10.1016/j.nbd.2010.04.014.

Antioxidants combined with behavioral enrichment can slow brain aging. Head E. Aging and Age-Related Disorders (Bondy S, Maiese K eds); Humana Press. 2010 Jul 31; pp 381-397. ISBN: 978-1-60761-601-6, DOI: 10.1007/978-1-60761-602-3_19.

Synergistic effects of long-term antioxidant diet and behavioral enrichment on β-amyloid load and non-amyloidogenic processing in aged canines. Pop V, Head E, Hill MA, Gillen D, Berchtold NC, Muggenburg BA, Milgram NW, Murphy MP, Cotman CW. J Neurosci. 2010 Jul 21; 30(29):9831-9. PMID: 20660265, DOI: 10.1523/JNEUROSCI.6194-09.2010.

Systemic mitochondrial dysfunction and the etiology of Alzheimer’s disease and down syndrome dementia. Coskun PE, Wyrembak J, Derbereva O, Melkonian G, Doran E, Lott IT, Head E, Cotman CW, Wallace DC. J Alzheimers Dis. 2010 Jun 3; 20 Suppl 2(0 2):S293-310. PMID: 20463402, DOI: 10.3233/JAD-2010-100351.

Amyloid-β peptide and oligomers in the brain and cerebrospinal fluid of aged canines. Head E, Pop V, Sarsoza F, Kayed R, Beckett TL, Studzinski CM, Tomic JL, Glabe CG, Murphy MP. J Alzheimers Dis. 2010 Apr 1; 20(2):637-46. PMID: 20164551, DOI: 10.3233/JAD-2010-1397.

Pharmacological models for preclinical testing: from mouse to dog to nonhuman primates. Eriksen JL, Murphy MP, Head E. BACE: Lead Target for Orchestrated Therapy of Alzheimer’s Disease (John V ed); Wiley. 2010 Fed 11; ch 7, pp 159-176. ISBN: 978-0-470-29342-3, DOI: 9780470594087.ch7.

Neuropathological heterogeneity in frontotemporal lobar degeneration with TDP-43 proteinopathy: a quantitative study of 94 cases using principal components analysis. Armstrong RA, Ellis W, Hamilton RL, Mackenzie IR, Hedreen J, Gearing M, Montine T, Vonsattel JP, Head E, Lieberman AP, Cairns NJ. J Neural Transm (Vienna). 2010 Feb; 117(2):227-39. Epub 2009 Dec 10. PMID: 20012109, DOI: 10.1007/s00702-009-0350-6.

Cognitive dysfunction in aged dogs. Head E, Landsberg G. Textbook of Veterinary Internal Medicine, 7th ed (Ettinger SJ, Feldman EC eds); Saunders. 2010 Jan 7; ch 60, pp 238-239. ISBN: 978-1-4160-6593-7, Link: 4Qzau1jagOYC.

Micronutrient antioxidants, cognition, and neuropathology: a longitudinal study in the canine model of human aging. Opii WO, Head E. Micronutrients and Brain Health, 1st ed (Packer L, Sies H, Eggersdorfer M, Cadenas E eds); CRC Press. 2010; ch 5, pp 1-7. Pub 2009 Oct 6. ISBN: 978-1-4200-7351-5, Link: HZI3EQAAQBAJ.

Short-term supplementation with acetyl-L-carnitine and lipoic acid alters plasma protein carbonyl levels but does not improve cognition in aged beagles. Christie LA, Opii WO, Head E, Araujo JA, de Rivera C, Milgram NW, Cotman CW. Exp Gerontol. 2009 Dec; 44(12):752-9. Epub 2009 Sep 6. PMID: 19735717, DOI: 10.1016/j.exger.2009.08.012.

Effects of age, dietary, and behavioral enrichment on brain mitochondria in a canine model of human aging. Head E, Nukala VN, Fenoglio KA, Muggenburg BA, Cotman CW, Sullivan PG. Exp Neurol. 2009 Nov; 220(1):171-6. Epub 2009 Aug 22. PMID: 19703441, DOI: 10.1016/j.expneurol.2009.08.014.

Nutrition, brain aging, and neurodegeneration. Joseph J, Cole G, Head E, Ingram D. J Neurosci. 2009 Oct 14; 29(41):12795-801. PMID: 19828791, DOI: 10.1523/JNEUROSCI.3520-09.2009.

Aging, neurodegenerative disease and β-secretase. Murphy MP, Ahmed RR, Webb RL, Holler CJ, Li F, Beckett TL, Niedowicz DM, Studzinski CM, Head E. New Trends in Alzheimer and Parkinson Related Disorders: ADPD 2009 (Fisher A, Hanin I eds); Medimond, Bologna Italy. 2009 Oct; ch 13, pp 65-68. ISBN: unknown, Link: 2009-Fisher-Hanin-index.

A fibril-specific, conformation-dependent antibody recognizes a subset of Aβ plaques in Alzheimer disease, Down syndrome and Tg2576 transgenic mouse brain. Sarsoza F, Saing T, Kayed R, Dahlin R, Dick M, Broadwater-Hollifield C, Mobley S, Lott I, Doran E, Gillen D, Anderson-Bergman C, Cribbs DH, Glabe C, Head. E Acta Neuropathol. 2009 Oct; 118(4):505-17. Epub 2009 Apr 10. PMID: 19360426, DOI: 10.1007/s00401-009-0530-3.

Strategies for improving cognition with aging: insights from a longitudinal study of antioxidant and behavioral enrichment in canines. Christie LA, Opii WO, Head E. Age (Dordr). 2009 Sep; 31(3):211-20. Epub 2008 Jun 22. PMID: 19714491, DOI: 10.1007/s11357-008-9063-2.

Soluble fibrillar oligomer levels are elevated in Alzheimer’s disease brain and correlate with cognitive dysfunction. Tomic JL, Pensalfini A, Head E, Glabe CG. Neurobiol Dis. 2009 Sep; 35(3):352-8. Epub 2009 Jun 10. PMID: 19523517, DOI: 10.1016/j.nbd.2009.05.024.

Synaptic proteins, neuropathology and cognitive status in the oldest-old. Head E, Corrada MM, Kahle-Wrobleski K, Kim RC, Sarsoza F, Goodus M, Kawas CH. Neurobiol Aging. 2009 Jul; 30(7):1125-34. Epub 2007 Nov 14. PMID: 18006193, DOI: 10.1016/j.neurobiolaging.2007.10.001.

Mild cognitive impairment: pivotal cingulate damage in amnestic and dysexecutive subgroups. Johnson JK, Head E, Vogt BA. Cingulate Neurobiology and Disease (Vogt BA ed); Oxford. 2009 Jun 4; ch 33, pp 727-748. ISBN: 978-0-1985-6696-0, DOI: 9780198566960.003.0033.

Immunotherapy in a natural model of Aβ pathogenesis: the aging beagle. Vasilevko V, Head E. CNS Neurol Disord Drug Targets. 2009 Apr; 8(2):98-113. PMID: 19355931, DOI: 10.2174/187152709787847333.

Oxidative damage and cognitive dysfunction: antioxidant treatments to promote healthy brain aging. Head E. Neurochem Res. 2009 Apr; 34(4):670-8. Epub 2008 Aug 6. PMID: 18683046, DOI: 10.1007/s11064-008-9808-4.

APOE ε2 is associated with intact cognition but increased Alzheimer pathology in the oldest old. Berlau DJ, Corrada MM, Head E, Kawas CH. Neurology. 2009 Mar 3; 72(9):829-34. PMID: 19255410, DOI: 10.1212/01.wnl.0000343853.00346.a4.

Annular protofibrils are a structurally and functionally distinct type of amyloid oligomer. Kayed R, Pensalfini A, Margol L, Sokolov Y, Sarsoza F, Head E, Hall J, Glabe C. J Biol Chem. 2009 Feb 13; 284(7):4230-7. Epub 2008 Dec 18. PMID: 19098006, DOI: 10.1074/jbc.M808591200.

Caspase cleavage of the amyloid precursor protein is prevented after overexpression of bcl-2 in a triple transgenic mouse model of Alzheimer’s disease. Kumasaka DK, Galvan V, Head E, Rohn TT. Int J Physiol Pathophysiol Pharmacol. 2009 Jan 12; 1(1):48-56. PMID: 20411026, Link: PMC2856934.

Caspases as therapeutic targets in Alzheimer’s disease: is it time to “cut” to the chase? Rohn TT, Head E. Int J Clin Exp Pathol. 2009; 2(2):108-18. Epub 2008 Jun 10. PMID: 19079646, Link: PMC2583629.

Degeneration in canine brain aging. Head E. From Development to Degeneration and Regeneration of the Nervous System (Ribak CE, de la Hoz CA, Jones EG, Larriva-Sahd JA, Swanson LW eds); Oxford. 2008 Dec 18; ch 9, pp 171-182. ISBN: 978-0-1953-6900-7, DOI: 9780195369007.003.0009.

The canine (dog) model of human aging and disease: dietary, environmental and immunotherapy approaches. Cotman CW, Head E. J Alzheimers Dis. 2008 Dec 17; 15(4):685-707. PMID: 19096165, DOI: 10.3233/jad-2008-15413.

Rhinal and dorsolateral prefrontal cortex lesions produce selective impairments in object and spatial learning and memory in canines. Christie LA, Saunders RC, Kowalska DM, MacKay WA, Head E, Cotman CW. J Comp Neurol. 2008 Nov 10; 511(2):257-70. PMID: 18792072, DOI: 10.1002/cne.21821.

Gene expression changes in the course of normal brain aging are sexually dimorphic. Berchtold NC, Cribbs DH, Coleman PD, Rogers J, Head E, Kim R, Beach T, Miller C, Troncoso J, Trojanowski JQ, Zielke HR, Cotman CW. Proc Natl Acad Sci U S A. 2008 Oct 7; 105(40):15605-10. Epub 2008 Oct 1. PMID: 18832152, DOI: 10.1073/pnas.0806883105.

Protective effects of R-alpha-lipoic acid and acetyl-L-carnitine in MIN6 and isolated rat islet cells chronically exposed to oleic acid. Shen W, Liu K, Tian C, Yang L, Li X, Ren J, Packer L, Head E, Sharman E, Liu J. J Cell Biochem. 2008 Jul 1; 104(4):1232-43. PMID: 18260126, DOI: 10.1002/jcb.21701.

Reducing AD-like pathology in 3xTg-AD mouse model by DNA epitope vaccine — a novel immunotherapeutic strategy. Movsesyan N, Ghochikyan A, Mkrtichyan M, Petrushina I, Davtyan H, Olkhanud PB, Head E, Biragyn A, Cribbs DH, Agadjanyan MG. PLoS One. 2008 May 7; 3(5):e2124. PMID: 18461171, DOI: 10.1371/journal.pone.0002124.

A two-year study with fibrillar β-amyloid (Aβ) immunization in aged canines: effects on cognitive function and brain Aβ. Head E, Pop V, Vasilevko V, Hill M, Saing T, Sarsoza F, Nistor M, Christie LA, Milton S, Glabe C, Barrett E, Cribbs D. J Neurosci. 2008 Apr 2; 28(14):3555-66. PMID: 18385314, DOI: 10.1523/JNEUROSCI.0208-08.2008.

Lack of pathology in a triple transgenic mouse model of Alzheimer’s disease after overexpression of the anti-apoptotic protein Bcl-2. Rohn TT, Vyas V, Hernandez-Estrada T, Nichol KE, Christie LA, Head E. J Neurosci. 2008 Mar 19; 28(12):3051-9. PMID: 18354008, DOI: 10.1523/JNEUROSCI.5620-07.2008.

Neuroimaging of individuals with Down’s syndrome at-risk for dementia: evidence for possible compensatory events. Haier RJ, Head K, Head E, Lott IT. Neuroimage. 2008 Feb 1; 39(3):1324-32. Epub 2007 Oct 12. PMID: 18006337, DOI: 10.1016/j.neuroimage.2007.09.064.

Caspase activation in Alzheimer’s disease: early to rise and late to bed. Rohn TT, Head E. Rev Neurosci. 2008; 19(6):383-93. PMID: 19317178, DOI: 10.1515/revneuro.2008.19.6.383.

Oxidative stress, aging, and central nervous system disease in the canine model of human brain aging. Head E, Rofina J, Zicker S. Vet Clin North Am Small Anim Pract. 2008 Jan; 38(1):167-78, vi. PMID: 18249248, DOI: 10.1016/j.cvsm.2007.10.002.

Region specific neuron loss in the aged canine hippocampus is reduced by enrichment. Siwak-Tapp CT, Head E, Muggenburg BA, Milgram NW, Cotman CW. Neurobiol Aging. 2008 Jan; 29(1):39-50. Epub 2006 Nov 7. PMID: 17092609, DOI: 10.1016/j.neurobiolaging.2006.09.018.

Proteomic identification of brain proteins in the canine model of human aging following a long-term treatment with antioxidants and a program of behavioral enrichment: relevance to Alzheimer’s disease. Opii WO, Joshi G, Head E, Milgram NW, Muggenburg BA, Klein JB, Pierce WM, Cotman CW, Butterfield DA. Neurobiol Aging. 2008 Jan; 29(1):51-70. Epub 2006 Oct 20. PMID: 17055614, DOI: 10.1016/j.neurobiolaging.2006.09.012.

Alzheimer’s disease peptide epitope vaccine reduces insoluble but not soluble/oligomeric Aβ species in amyloid precursor protein transgenic mice. Petrushina I, Ghochikyan A, Mktrichyan M, Mamikonyan G, Movsesyan N, Davtyan H, Patel A, Head E, Cribbs DH, Agadjanyan MG. J Neurosci. 2007 Nov 14; 27(46):12721-31. PMID: 18003852, DOI: 10.1523/JNEUROSCI.3201-07.2007.

Combining an antioxidant-fortified diet with behavioral enrichment leads to cognitive improvement and reduced brain pathology in aging canines: strategies for healthy aging. Head E. Ann N Y Acad Sci. 2007 Oct; 1114:398-406. Epub 2007 Aug 23. PMID: 17717087, DOI: 10.1196/annals.1396.004.

Cognitive dysfunction and the neurobiology of ageing in cats. Gunn-Moore D, Moffat K, Christie LA, Head E. J Small Anim Pract. 2007 Oct; 48(10):546-53. Epub 2007 Jul 6. PMID: 17617164, DOI: 10.1111/j.1748-5827.2007.00386.x.

Alpha- and beta-secretase activity as a function of age and beta-amyloid in Down syndrome and normal brain. Nistor M, Don M, Parekh M, Sarsoza F, Goodus M, Lopez GE, Kawas C, Leverenz J, Doran E, Lott IT, Hill M, Head E. Neurobiol Aging. 2007 Oct; 28(10):1493-506. Epub 2006 Aug 9. PMID: 16904243, DOI: 10.1016/j.neurobiolaging.2006.06.023.

Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. Kayed R, Head E, Sarsoza F, Saing T, Cotman CW, Necula M, Margol L, Wu J, Breydo L, Thompson JL, Rasool S, Gurlo T, Butler P, Glabe CG. Mol Neurodegener. 2007 Sep 26; 2:18. PMID: 17897471, DOI: 10.1186/1750-1326-2-18.

Neurogenesis decreases with age in the canine hippocampus and correlates with cognitive function. Siwak-Tapp CT, Head E, Muggenburg BA, Milgram NW, Cotman CW. Neurobiol Learn Mem. 2007 Sep; 88(2):249-59. Epub 2007 Jun 22. PMID: 17587610, DOI: 10.1016/j.nlm.2007.05.001.

Dissociation of neuropathologic findings and cognition: case report of an apolipoprotein E ε2/ε2 genotype. Berlau DJ, Kahle-Wrobleski K, Head E, Goodus M, Kim R, Kawas C. Arch Neurol. 2007 Aug; 64(8):1193-6. PMID: 17698712, DOI: 10.1001/archneur.64.8.1193.

Radiotracers for a multi-target approach to the diagnosis of Alzheimer’s disease. Mukherjee J, Head E, Pichika R, Easwaramoorthy B, Collins D, Chen I, Wang CS, Saigal N, Trinidad P, Kim K, Nguyen VL. J Label Compd Radiopharm. 2007 Jul 30; 50(5-6):375-379. DOI: 10.1002/jlcr.1266.

Possible compensatory events in adult Down syndrome brain prior to the development of Alzheimer disease neuropathology: targets for nonpharmacological intervention. Head E, Lott IT, Patterson D, Doran E, Haier RJ. J Alzheimers Dis. 2007 Mar; 11(1):61-76. PMID: 17361036, DOI: 10.3233/jad-2007-11110.

Frontal variant of Alzheimer’s disease. Johnson JK, Brun A, Head E. The Human Frontal Lobes: Functions and Disorders, 2nd ed (Miller BL, Cummings JL eds); Guilford Press. 2007; ch 28, pp 429-444. Pub 2006 Nov 30. ISBN: 978-1-5938-5329-7, Link: Chapter 28.

Beta-amyloid, oxidative stress and down syndrome. Lott IT, Head E, Doran E, Busciglio J. Curr Alzheimer Res. 2006 Dec; 3(5):521-8. PMID: 17168651, DOI: 10.2174/156720506779025305.

BioVision: an application for the automated image analysis of histological sections. Chubb C, Inagaki Y, Sheu P, Cummings B, Wasserman A, Head E, Cotman C. Neurobiol Aging. 2006 Oct; 27(10):1462-76. Epub 2005 Nov 4. PMID: 16271803, DOI: 10.1016/j.neurobiolaging.2005.08.023.

Visuospatial function in the beagle dog: an early marker of cognitive decline in a model of human aging and dementia. Studzinski CM, Christie LA, Araujo JA, Burnham WM, Head E, Cotman CW, Milgram NW. Neurobiol Learn Mem. 2006 Sep; 86(2):197-204. Epub 2006 Apr 17. PMID: 16616528, DOI: 10.1016/j.nlm.2006.02.005.

Neuroprotective effects of cognitive enrichment. Milgram NW, Siwak-Tapp CT, Araujo J, Head E. Ageing Res Rev. 2006 Aug; 5(3):354-69. Epub 2006 Sep 1. PMID: 16949888, DOI: 10.1016/j.arr.2006.04.004.

Relapsing polychondritis with features of dementia with Lewy bodies. Head E, Starr A, Kim RC, Parachikova A, Lopez GE, Dick M, Cribbs DH. Acta Neuropathol. 2006 Aug; 112(2):217-25. Epub 2006 Jul 11. PMID: 16832629, DOI: 10.1007/s00401-006-0098-0.

Ageing changes in cat brains demonstrated by β-amyloid and AT8-immunoreactive phosphorylated tau deposits. Gunn-Moore DA, McVee J, Bradshaw JM, Pearson GR, Head E, Gunn-Moore FJ. J Feline Med Surg. 2006 Aug; 8(4):234-42. Epub 2006 Apr 17. PMID: 16603401, DOI: 10.1016/j.jfms.2006.01.003.

Immunization with fibrillar Aβ₁⎽₄₂ in young and aged canines: Antibody generation and characteristics, and effects on CSF and brain Aβ. Head E, Barrett EG, Murphy MP, Das P, Nistor M, Sarsoza F, Glabe CC, Kayed R, Milton S, Vasilevko V, Milgram NW, Agadjanyan MG, Cribbs DH, Cotman CW. Vaccine. 2006 Apr 5; 24(15):2824-34. Epub 2006 Jan 19. PMID: 16460841, DOI: 10.1016/j.vaccine.2005.12.058.

Caspase-mediated cleavage of glial fibrillary acidic protein within degenerating astrocytes of the Alzheimer’s disease brain. Mouser PE, Head E, Ha KH, Rohn TT. Am J Pathol. 2006 Mar; 168(3):936-46. PMID: 16507909, DOI: 10.2353/ajpath.2006.050798.

Nutritional antioxidant enrichment and improved cognitive function in canines. Head E, Cotman CW. Oxidative Stress and Age-Related Neurodegeneration, 1st ed (Luo Y, Packer L eds); CRC Press. 2006; ch 12, pp 213-223. Pub 2005 Nov 21. ISBN: 978-0-8493-3725-3, Link: ruPLBQAAQBAJ.

Application of an automated voxel-based morphometry technique to assess regional gray and white matter brain atrophy in a canine model of aging. Tapp PD, Head K, Head E, Milgram NW, Muggenburg BA, Su MY. Neuroimage. 2006 Jan 1; 29(1):234-44. Epub 2005 Nov 7. PMID: 16275022, DOI: 10.1016/j.neuroimage.2005.07.043.

Nutritional management of brain aging in dogs. Roudebush P, Zicker SC, Cotman CW, Milgram NW, Muggenburg BA, Head E. J Am Vet Med Assoc. 2005 Sep 1; 227(5):722-8. PMID: 16178393, DOI: 10.2460/javma.2005.227.722.

Caspase-cleaved tau accumulation in neurodegenerative diseases associated with tau and α-synuclein pathology. Newman J, Rissman RA, Sarsoza F, Kim RC, Dick M, Bennett DA, Cotman CW, Rohn TT, Head E. Acta Neuropathol. 2005 Aug; 110(2):135-44. Epub 2005 Jun 29. PMID: 15986225, DOI: 10.1007/s00401-005-1027-3.

The use of dietary antioxidants and mitochondrial co-factors to promote successful aging. Head E, Cotman CW, Zicker SC, Milgram NW. Curr Top Nutraceutical Res. 2005 May; 3(2):85-94. Link: 19044366118

β-amyloid deposition and tau phosphorylation in clinically characterized aged cats. Head E, Moffat K, Das P, Sarsoza F, Poon WW, Landsberg G, Cotman CW, Murphy MP. Neurobiol Aging. 2005 May; 26(5):749-63. Epub 2004 Oct 28. PMID: 15708450, DOI: 10.1016/j.neurobiolaging.2004.06.015.

Assessment of nutritional interventions for modification of age-associated cognitive decline using a canine model of human aging. Araujo JA, Studzinski CM, Head E, Cotman CW, Milgram NW. Age (Dordr). 2005 Mar; 27(1):27-37. Epub 2005 May 2. PMID: 23598601, DOI: 10.1007/s11357-005-4001-z.

ets-2 promotes the activation of a mitochondrial death pathway in Down’s syndrome neurons. Helguera P, Pelsman A, Pigino G, Wolvetang E, Head E, Busciglio J. J Neurosci. 2005 Mar 2; 25(9):2295-303. PMID: 15745955, DOI: 10.1523/JNEUROSCI.5107-04.2005.

Learning and memory as a function of age in Down syndrome: a study using animal-based tasks. Nelson L, Johnson JK, Freedman M, Lott I, Groot J, Chang M, Milgram NW, Head E. Prog Neuropsychopharmacol Biol Psychiatry. 2005 Mar 2; 29(3):443-53. PMID: 15795053, DOI: 10.1016/j.pnpbp.2004.12.009.

Chronic antioxidant and mitochondrial cofactor administration improves discrimination learning in aged but not young dogs. Siwak CT, Tapp PD, Head E, Zicker SC, Murphey HL, Muggenburg BA, Ikeda-Douglas CJ, Cotman CW, Milgram NW. Prog Neuropsychopharmacol Biol Psychiatry. 2005 Mar; 29(3):461-9. Epub 2005 Feb 16. PMID: 15795055, DOI: 10.1016/j.pnpbp.2004.12.011.

A comparison of egocentric and allocentric age-dependent spatial learning in the beagle dog. Christie LA, Studzinski CM, Araujo JA, Leung CS, Ikeda-Douglas CJ, Head E, Cotman CW, Milgram NW. Prog Neuropsychopharmacol Biol Psychiatry. 2005 Mar; 29(3):361-9. Epub 2005 Feb 16. PMID: 15795044, DOI: 10.1016/j.pnpbp.2004.12.002.

Effects of scopolamine challenge on regional cerebral blood volume. A pharmacological model to validate the use of contrast enhanced magnetic resonance imaging to assess cerebral blood volume in a canine model of aging. Tapp PD, Chu Y, Araujo JA, Chiou JY, Head E, Milgram NW, Su MY. Prog Neuropsychopharmacol Biol Psychiatry. 2005 Mar; 29(3):399-406. Epub 2005 Feb 12. PMID: 15795048, DOI: 10.1016/j.pnpbp.2004.12.006.

A longitudinal study of brain morphometrics using serial magnetic resonance imaging analysis in a canine model of aging. Su MY, Tapp PD, Vu L, Chen YF, Chu Y, Muggenburg B, Chiou JY, Chen C, Wang J, Bracco C, Head E. Prog Neuropsychopharmacol Biol Psychiatry. 2005 Mar; 29(3):389-97. Epub 2005 Feb 12. PMID: 15795047, DOI: 10.1016/j.pnpbp.2004.12.005.

Alzheimer disease and Down syndrome: factors in pathogenesis. Lott IT, Head E. Neurobiol Aging. 2005 Mar; 26(3):383-9. Epub 2004 Nov 16. PMID: 15639317, DOI: 10.1016/j.neurobiolaging.2004.08.005.

Reduced neuronal expression of synaptic transmission modulator HNK-1/neural cell adhesion molecule as a potential consequence of amyloid β-mediated oxidative stress: a proteomic approach. Thomas SN, Soreghan BA, Nistor M, Sarsoza F, Head E, Yang AJ. J Neurochem. 2005 Feb; 92(4):705-17. PMID: 15686472, DOI: 10.1111/j.1471-4159.2004.02892.x.

Learning ability in aged beagle dogs is preserved by behavioral enrichment and dietary fortification: a two-year longitudinal study. Milgram NW, Head E, Zicker SC, Ikeda-Douglas CJ, Murphey H, Muggenburg B, Siwak C, Tapp D, Cotman CW. Neurobiol Aging. 2005 Jan; 26(1):77-90. PMID: 15585348, DOI: 10.1016/j.neurobiolaging.2004.02.014.

Cognitive dysfunction in aged dogs. Head E, Landsberg G. Textbook of Veterinary Internal Medicine, 6th ed (Ettinger SJ, Feldman EC eds); Saunders. 2005; ch 51, pp 181-182. Pub 2004 Nov 9. ISBN: 978-1-4160-0110-2.

Comparison of the effects of L-carnitine and acetyl-L-carnitine on carnitine levels, ambulatory activity, and oxidative stress biomarkers in the brain of old rats. Liu J, Head E, Kuratsune H, Cotman CW, Ames BN. Ann N Y Acad Sci. 2004 Nov; 1033:117-31. PMID: 15591009, DOI: 10.1196/annals.1320.011.

Frontal lobe volume, function, and β-amyloid pathology in a canine model of aging. Tapp PD, Siwak CT, Gao FQ, Chiou JY, Black SE, Head E, Muggenburg BA, Cotman CW, Milgram NW, Su MY. J Neurosci. 2004 Sep 22; 24(38):8205-13. PMID: 15385603, DOI: 10.1523/JNEUROSCI.1339-04.2004.

Concept abstraction in the aging dog: development of a protocol using successive discrimination and size concept tasks. Tapp PD, Siwak CT, Head E, Cotman CW, Murphey H, Muggenburg BA, Ikeda-Douglas C, Milgram NW. Behav Brain Res. 2004 Aug 12; 153(1):199-210. PMID: 15219721, DOI: 10.1016/j.bbr.2003.12.003.

Isolated executive impairment and associated frontal neuropathology. Johnson JK, Vogt BA, Kim R, Cotman CW, Head E. Dement Geriatr Cogn Disord. 2004 Jun 10; 17(4):360-7. PMID: 15178954, DOI: 10.1159/000078183.

Long-term treatment with antioxidants and a program of behavioral enrichment reduces age-dependent impairment in discrimination and reversal learning in beagle dogs. Milgram NW, Head E, Zicker SC, Ikeda-Douglas C, Murphey H, Muggenberg BA, Siwak CT, Tapp PD, Lowry SR, Cotman CW. Exp Gerontol. 2004 May; 39(5):753-65. PMID: 15130670, DOI: 10.1016/j.exger.2004.01.007.

Down syndrome and beta-amyloid deposition. Head E, Lott IT. Curr Opin Neurol. 2004 Apr; 17(2):95-100. PMID: 15021233, DOI: 10.1097/00019052-200404000-00003.

Nutraceuticals, aging, and cognitive dysfunction. Head E, Zicker SC. Vet Clin North Am Small Anim Pract. 2004 Jan; 34(1):217-28. PMID: 15032129, DOI: 10.1016/j.cvsm.2003.09.007.

Aging and effects on behavior, 2nd ed. Landsberg GM, Head E. Geriatrics & Gerontology of the Dog and Cat (Hoskins JD ed); Saunders. 2004; ch 4, pp 29-42. Pub 2003 Dec 8. ISBN: 978-0-7216-8799-5, DOI: B978-0-7216-8799-5.50007-5.

Temporal cortex hypermetabolism in Down syndrome prior to the onset of dementia. Haier RJ, Alkire MT, White NS, Uncapher MR, Head E, Lott IT, Cotman CW. Neurology. 2003 Dec 23; 61(12):1673-9. PMID: 14694028, DOI: 10.1212/01.wnl.0000098935.36984.25.

Accumulation of caspase cleaved amyloid precursor protein represents an early neurodegenerative event in aging and in Alzheimer’s disease. Zhao M, Su J, Head E, Cotman CW. Neurobiol Dis. 2003 Dec; 14(3):391-403. PMID: 14678756, DOI: 10.1016/j.nbd.2003.07.006.

Generation and characterization of the humoral immune response to DNA immunization with a chimeric β-amyloid-interleukin-4 minigene. Ghochikyan A, Vasilevko V, Petrushina I, Movsesyan N, Babikyan D, Tian W, Sadzikava N, Ross TM, Head E, Cribbs DH, Agadjanyan MG. Eur J Immunol. 2003 Dec; 33(12):3232-41. PMID: 14635031, DOI: 10.1002/eji.200324000.

Response latency in Canis familiaris: mental ability or mental strategy? Nippak PM, Chan AD, Campbell Z, Muggenburg B, Head E, Ikeda-Douglas CJ, Murphey H, Cotman CW, Milgram NW. Behav Neurosci. 2003 Oct; 117(5):1066-75. PMID: 14570555, DOI: 10.1037/0735-7044.117.5.1066.

Spatial patterns of mammalian brain aging: distribution of cathepsin D-immunoreactive cell bodies and dystrophic dendrites in aging dogs resembles that in Alzheimer’s disease. Bi X, Head E, Cotman CW, Lynch G. J Comp Neurol. 2003 Sep 22; 464(3):371-81. PMID: 12900930, DOI: 10.1002/cne.10795.

Parallel compensatory and pathological events associated with tau pathology in middle aged individuals with Down syndrome. Head E, Lott IT, Hof PR, Bouras C, Su JH, Kim R, Haier R, Cotman CW. J Neuropathol Exp Neurol. 2003 Sep; 62(9):917-26. PMID: 14533781, DOI: 10.1093/jnen/62.9.917.

Locomotor activity rhythms in dogs vary with age and cognitive status. Siwak CT, Tapp PD, Zicker SC, Murphey HL, Muggenburg BA, Head E, Cotman CW, Milgram NW. Behav Neurosci. 2003 Aug; 117(4):813-24. PMID: 12931965, DOI: 10.1037/0735-7044.117.4.813.

Identification of neuronal plasma membrane microdomains that colocalize β-amyloid and presenilin: implications for β-amyloid precursor protein processing. Torp R, Ottersen OP, Cotman CW, Head E. Neuroscience. 2003 Aug 22; 120(2):291-300. PMID: 12890502, DOI: 10.1016/s0306-4522(03)00320-8.

Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, Glabe CG. Science. 2003 Apr 18; 300(5618):486-9. PMID: 12702875, DOI: 10.1126/science.1079469.

Size and reversal learning in the beagle dog as a measure of executive function and inhibitory control in aging. Tapp PD, Siwak CT, Estrada J, Head E, Muggenburg BA, Cotman CW, Milgram NW. Learn Mem. 2003 Jan-Feb; 10(1):64-73. PMID: 12551965, DOI: 10.1101/lm.54403.

Caspase activation in the Alzheimer’s disease brain: tortuous and torturous. Rohn TT, Rissman RA, Head E, Cotman CW. Drug News Perspect. 2002 Nov; 15(9):549-557. PMID: 12677194, DOI: 10.1358/dnp.2002.15.9.740233, Link: pjbf7k9rkk.

Caspase-9 activation and caspase cleavage of tau in the Alzheimer’s disease brain. Rohn TT, Rissman RA, Davis MC, Kim YE, Cotman CW, Head E. Neurobiol Dis. 2002 Nov; 11(2):341-54. PMID: 12505426, DOI: 10.1006/nbdi.2002.0549.

Atherosclerotic lesions and mitochondria DNA deletions in brain microvessels as a central target for the development of human AD and AD-like pathology in aged transgenic mice. Aliev G, Seyidova D, Neal ML, Shi J, Lamb BT, Siedlak SL, Vinters HV, Head E, Perry G, Lamanna JC, Friedland RP, Cotman CW. Ann N Y Acad Sci. 2002 Nov; 977(1):45-64. PMID: 12480733, DOI: 10.1111/j.1749-6632.2002.tb04798.x.

Landmark discrimination learning in the dog: effects of age, an antioxidant fortified food, and cognitive strategy. Milgram NW, Head E, Muggenburg B, Holowachuk D, Murphey H, Estrada J, Ikeda-Douglas CJ, Zicker SC, Cotman CW. Neurosci Biobehav Rev. 2002 Oct; 26(6):679-95. PMID: 12479842, DOI: 10.1016/s0149-7634(02)00039-8.

Neurobiological basis for cognitive dysfunction in aging dogs: identifying strategies to promote successful aging. Head E. Gerontology: Prolonging Health through Nutrition (2001 Nestlé Purina Nutrition Forum Proceedings: A Supplement to Compendium on Continuing Education for the Practicing Veterinarian), 2002 Oct; 24(9A):35-9.

β-amyloid deposition and neurofibrillary tangle association with caspase activation in Down syndrome. Head E, Lott IT, Cribbs DH, Cotman CW, Rohn TT. Neurosci Lett. 2002 Sep 13; 330(1):99-103. PMID: 12213643, DOI: 10.1016/s0304-3940(02)00705-x.

Brain aging in the canine: a diet enriched in antioxidants reduces cognitive dysfunction. Cotman CW, Head E, Muggenburg BA, Zicker S, Milgram NW. Neurobiol Aging. 2002 Sep-Oct; 23(5):809-18. PMID: 12392784, DOI: 10.1016/s0197-4580(02)00073-8.

Dietary enrichment counteracts age-associated cognitive dysfunction in canines. Milgram NW, Zicker SC, Head E, Muggenburg BA, Murphey H, Ikeda-Douglas CJ, Cotman CW. Neurobiol Aging. 2002 Sep-Oct; 23(5):737-45. PMID: 12392778, DOI: 10.1016/s0197-4580(02)00020-9.

Oxidative damage increases with age in a canine model of human brain aging. Head E, Liu J, Hagen TM, Muggenburg BA, Milgram NW, Ames BN, Cotman CW. J Neurochem. 2002 Jul; 82(2):375-81. PMID: 12124438, DOI: 10.1046/j.1471-4159.2002.00969.x.

Caspase-cleaved amyloid precursor protein and activated caspase-3 are co-localized in the granules of granulovacuolar degeneration in Alzheimer’s disease and Down’s syndrome brain. Su JH, Kesslak JP, Head E, Cotman CW. Acta Neuropathol. 2002 Jul; 104(1):1-6. Epub 2002 May 9. PMID: 12070657, DOI: 10.1007/s00401-002-0548-2.

Visuospatial impairments in aged canines (Canis familiaris): the role of cognitive-behavioral flexibility. Chan AD, Nippak PM, Murphey H, Ikeda-Douglas CJ, Muggenburg B, Head E, Cotman CW, Milgram NW. Behav Neurosci. 2002 Jun; 116(3):443-54. PMID: 12049325, DOI: 0735-7044.116.3.443.

Memory loss in old rats is associated with brain mitochondrial decay and RNA/DNA oxidation: partial reversal by feeding acetyl-L-carnitine and/or R-α-lipoic acid. Liu J, Head E, Gharib AM, Yuan W, Ingersoll RT, Hagen TM, Cotman CW, Ames BN. Proc Natl Acad Sci U S A. 2002 Feb 19; 99(4):2356-61. PMID: 11854529, DOI: 10.1073/pnas.261709299.

Insights into Aβ and presenilin from a canine model of human brain aging. Head E, Torp R. Neurobiol Dis. 2002 Feb; 9(1):1-10. PMID: 11848680, DOI: 10.1006/nbdi.2002.0476.

Activation of caspase-8 in the Alzheimer’s disease brain. Rohn TT, Head E, Nesse WH, Cotman CW, Cribbs DH. Neurobiol Dis. 2001 Dec; 8(6):1006-16. PMID: 11741396, DOI: 10.1006/nbdi.2001.0449.

Oxidation of Aβ and plaque biogenesis in Alzheimer’s disease and Down syndrome. Head E, Garzon-Rodriguez W, Johnson JK, Lott IT, Cotman CW, Glabe C. Neurobiol Dis. 2001 Oct; 8(5):792-806. PMID: 11592849, DOI: 10.1006/nbdi.2001.0431.

Down syndrome and Alzheimer’s disease: a link between development and aging. Lott IT, Head E. Ment Retard Dev Disabil Res Rev. 2001 Aug 31; 7(3):172-8. PMID: 11553933, DOI: 10.1002/mrdd.1025.

Age dependent cognitive dysfunction in canines: dietary intervention. Milgram NW, Head E, Cotman CW, Zicker SC. Proceedings of the Third International Congress on Veterinary Behavioural Medicine, Vancouver BC (Overall KL, Mills DS, Heath SE, Horwitz D eds); Universities Federation for Animal Welfare: Wheathampstead UK. 2001 Aug 7-8; pp 53-7.

Brain aging in dogs: parallels with human brain aging and Alzheimer’s disease. Head E. Vet Ther. 2001 Summer; 2(3):247-60. PMID: 19746668.

Complement association with neurons and β-amyloid deposition in the brains of aged individuals with Down syndrome. Head E, Azizeh BY, Lott IT, Tenner AJ, Cotman CW, Cribbs DH. Neurobiol Dis. 2001 Apr; 8(2):252-65. PMID: 11300721, DOI: 10.1006/nbdi.2000.0380.

Correlation between caspase activation and neurofibrillary tangle formation in Alzheimer’s disease. Rohn TT, Head E, Su JH, Anderson AJ, Bahr BA, Cotman CW, Cribbs DH. Am J Pathol. 2001 Jan; 158(1):189-98. PMID: 11141492, DOI: 10.1016/S0002-9440(10)63957-0.

Neurobiological models of aging in the dog and other vertebrate species. Head E, Milgram NW, Cotman CW. Functional Neurobiology of Aging (Hof PR, Mobbs CV, eds); Academic Press. 2001; ch 30, pp 457-468. Pub 2000 Dec 29. ISBN: 978-0-12-351830-9, DOI: 10.1016/B978-012351830-9/50032-9.

Ultrastructural analyses of β-amyloid in the aged dog brain: neuronal β-amyloid is localized to the plasma membrane. Torp R, Head E, Cotman CW. Prog Neuropsychopharmacol Biol Psychiatry. 2000 Jul; 24(5):801-10. PMID: 11191714, DOI: 10.1016/s0278-5846(00)00107-x.

Initiation and propagation of molecular cascades in human brain aging: insight from the canine model to promote successful aging. Head E, Thornton PL, Tong L, Cotman CW. Prog Neuropsychopharmacol Biol Psychiatry. 2000 Jul; 24(5):777-86. PMID: 11191712, DOI: 10.1016/s0278-5846(00)00105-6.

Development of a protocol for studying object recognition memory in the dog. Callahan H, Ikeda-Douglas C, Head E, Cotman CW, Milgram NW. Prog Neuropsychopharmacol Biol Psychiatry. 2000 Jul; 24(5):693-707. PMID: 11191709, DOI: 10.1016/s0278-5846(00)00102-0.

Canine cognition, aging and neuropathology. Introduction. Head E, Cotman CW, Milgram NW. Prog Neuropsychopharmacol Biol Psychiatry. 2000 Jul; 24(5):671-3. PMID: 11191707, DOI: 10.1016/s0278-5846(00)00100-7.

Topography, histology, and seminology in dementia — reply. Johnson JK, Head E, Kim R, Starr A, Cotman CW. Arch Neurol. 2000 Jun; 57(6):899-900. PMID: 10867791, Link: 776548.

Molecular dating of senile plaques in the brains of individuals with Down syndrome and in aged dogs. Azizeh BY, Head E, Ibrahim MA, Torp R, Tenner AJ, Kim RC, Lott IT, Cotman CW. Exp Neurol. 2000 May; 163(1):111-22. PMID: 10785449, DOI: 10.1006/exnr.2000.7359.

Ultrastructural evidence of fibrillar β-amyloid associated with neuronal membranes in behaviorally characterized aged dog brains. Torp R, Head E, Milgram NW, Hahn F, Ottersen OP, Cotman CW. Neuroscience. 2000 Mar; 96(3):495-506. PMID: 10717430, DOI: 10.1016/s0306-4522(99)00568-0.

Use of a delayed non-matching to position task to model age-dependent cognitive decline in the dog. Adams B, Chan A, Callahan H, Siwak C, Tapp D, Ikeda-Douglas C, Atkinson P, Head E, Cotman CW, Milgram NW. Behav Brain Res. 2000 Feb; 108(1):47-56. PMID: 10680756, DOI: 10.1016/s0166-4328(99)00132-1.

Region-specific age at onset of β-amyloid in dogs. Head E, McCleary R, Hahn FF, Milgram NW, Cotman CW. Neurobiol Aging. 2000 Jan-Feb; 21(1):89-96. PMID: 10794853, DOI: 10.1016/s0197-4580(00)00093-2.

Clinical and pathological evidence for a frontal variant of Alzheimer disease. Johnson JK, Head E, Kim R, Starr A, Cotman CW. Arch Neurol. 1999 Oct; 56(10):1233-9. PMID: 10520939, DOI: 10.1001/archneur.56.10.1233.

The presence of isoaspartic acid in β-amyloid plaques indicates plaque age. Fonseca MI, Head E, Velazquez P, Cotman CW, Tenner AJ. Exp Neurol. 1999 Jun; 157(2):277-88. PMID: 10364440, DOI: 10.1006/exnr.1999.7058.

Landmark discrimination learning in the dog. Milgram NW, Adams B, Callahan H, Head E, Mackay B, Thirlwell C, Cotman CW. Learn Mem. 1999 Jan-Feb; 6(1):54-61. PMID: 0355524, DOI: 10.1101/lm.6.1.54.

Magnetic resonance imaging of anatomic and vascular characteristics in a canine model of human aging. Su MY, Head E, Brooks WM, Wang Z, Muggenburg BA, Adam GE, Sutherland R, Cotman CW, Nalcioglu O. Neurobiol Aging. 1998 Sep-Oct; 19(5):479-85. PMID: 9880050, DOI: 10.1016/s0197-4580(98)00081-5.

Visual-discrimination learning ability and β-amyloid accumulation in the dog. Head E, Callahan H, Muggenburg BA, Cotman CW, Milgram NW. Neurobiol Aging. 1998 Sep-Oct; 19(5):415-25. PMID: 9880044, DOI: 10.1016/s0197-4580(98)00084-0.

Selective loss of early suppression in the dentate gyrus precedes kainic acid induced electrographic seizures. Ikeda-Douglas CJ, Head E, Holsinger RM, Tremblay L, Racine R, Milgram NW. Epilepsy Res. 1998 Jul; 31(2):143-52. PMID: 9714506, DOI: 10.1016/s0920-1211(98)00028-x.

Therapeutic actions of L-deprenyl in dogs: a model of human brain aging. Ruehl WW, Neilson J, Hart B, Head E, Bruyette DS, Cummings BJ. Adv Pharmacol. 1998;42:316-9. ISBN: 978-0-12-032943-4. PMID: 9327904, DOI: 10.1016/s1054-3589(08)60753-x.

Effects of extended electrical kindling on exploratory behavior and spatial learning. Cammisuli S, Murphy MP, Ikeda-Douglas CJ, Balkissoon V, Holsinger RM, Head E, Michael M, Racine RJ, Milgram NW. Behav Brain Res. 1997 Dec; 89(1-2):179-90. PMID: 9475625, DOI: 10.1016/s0166-4328(97)00059-4.

The progression of β-amyloid deposition in the frontal cortex of the aged canine. Satou T, Cummings BJ, Head E, Nielson KA, Hahn FF, Milgram NW, Velazquez P, Cribbs DH, Tenner AJ, Cotman CW. Brain Res. 1997 Nov 7; 774(1-2):35-43. PMID: 9452189, DOI: 10.1016/s0006-8993(97)81684-8.

Open field activity and human interaction as a function of age and breed in dogs. Head E, Callahan H, Cummings BJ, Cotman CW, Ruehl WW, Muggenberg BA, Milgram NW. Physiol Behav. 1997 Nov; 62(5):963-71. PMID: 9333188, DOI: 10.1016/s0031-9384(97)00198-4.

Diffuse plaques contain C-terminal Aβ₄₂ and not Aβ₄₀: evidence from cats and dogs. Cummings BJ, Satou T, Head E, Milgram NW, Cole GM, Savage MJ, Podlisny MB, Selkoe DJ, Siman R, Greenberg BD, Cotman CW. Neurobiol Aging. 1996 Jul-Aug; 17(4):653-9. PMID: 8832640, DOI: 10.1016/0197-4580(96)00062-0.

β-amyloid accumulation correlates with cognitive dysfunction in the aged canine. Cummings BJ, Head E, Afagh AJ, Milgram NW, Cotman CW. Neurobiol Learn Mem. 1996 Jul; 66(1):11-23. PMID: 8661247, DOI: 10.1006/nlme.1996.0039.

The effects of L-deprenyl on spatial short term memory in young and aged dogs. Head E, Hartley J, Kameka AM, Mehta R, Ivy GO, Ruehl WW, Milgram NW. Prog Neuropsychopharmacol Biol Psychiatry. 1996 Apr; 20(3):515-30. PMID: 8771606, DOI: 10.1016/0278-5846(96)00014-0.

The canine as an animal model of human aging and dementia. Cummings BJ, Head E, Ruehl W, Milgram NW, Cotman CW. Neurobiol Aging. 1996 Mar-Apr; 17(2):259-68. PMID: 8744407, DOI: 10.1016/0197-4580(95)02060-8.

Canine cognitive dysfunction as a model for human age-related cognitive decline, dementia and Alzheimer’s disease: clinical presentation, cognitive testing, pathology and response to 1-deprenyl therapy. Ruehl WW, Bruyette DS, DePaoli A, Cotman CW, Head E, Milgram NW, Cummings BJ. Prog Brain Res. 1995 Dec 28; 106:ch 22, pp 217-25. ISBN: 978-0-444-81938-3, PMID: 8584657, DOI: 10.1016/s0079-6123(08)61218-2.

Spatial learning and memory as a function of age in the dog. Head E, Mehta R, Hartley J, Kameka M, Cummings BJ, Cotman CW, Ruehl WW, Milgram NW. Behav Neurosci. 1995 Oct; 109(5):851-8. PMID: 8554710, DOI: 10.1037//0735-7044.109.5.851.

Effects of chronic oral administration of L-deprenyl in the dog. Milgram NW, Ivy GO, Murphy MP, Head E, Wu PH, Ruehl WW, Yu PH, Durden DA, Davis BA, Boulton AA. Pharmacol Biochem Behav. 1995 Jun-Jul; 51(2-3):421-8. PMID: 7667363, DOI: 10.1016/0091-3057(94)00417-h.

Development of spontaneous seizures over extended electrical kindling. II. Persistence of dentate inhibitory suppression. Milgram NW, Michael M, Cammisuli S, Head E, Ferbinteanu J, Reid C, Murphy MP, Racine R. Brain Res. 1995 Jan 23; 670(1):112-20. PMID: 7719710, DOI: 10.1016/0006-8993(94)01277-o.

Effects of L-deprenyl on manifestations of aging in the rat and dog. Ivy GO, Rick JT, Murphy MP, Head E, Reid C, Milgram NW. Ann N Y Acad Sci. 1994 Jun 30; 717(1):45-59. PMID: 8030851, DOI: 10.1111/j.1749-6632.1994.tb12072.x.

Cognitive functions and aging in the dog: acquisition of nonspatial visual tasks. Milgram NW, Head E, Weiner E, Thomas E. Behav Neurosci. 1994 Feb; 108(1):57-68. PMID: 8192851, DOI: 10.1037//0735-7044.108.1.57.

(-)deprenyl increases activities of superoxide dismutase (SOD) in striatum of dog brain. Carrillo MC, Ivy GO, Milgram NW, Head E, Wu P, Kitani K. Life Sci. 1994; 54(20):1483-9. PMID: 8190023, DOI: 10.1016/0024-3205(94)90015-9.

The effect of L-deprenyl on behavior, cognitive function, and biogenic amines in the dog. Milgram NW, Ivy GO, Head E, Murphy MP, Wu PH, Ruehl WW, Yu PH, Durden DA, Davis BA, Paterson IA, Boulton AA. Neurochem Res. 1993 Dec; 18(12):1211-9. PMID: 8272186, DOI: 10.1007/BF00975038.

Changes in spontaneous behavior in the dog following oral administration of L-deprenyl. Head E, Milgram NW. Pharmacol Biochem Behav. 1992 Nov; 43(3):749-57. PMID: 1448469, DOI: 10.1016/0091-3057(92)90404-4.